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Abstract 
The common neurotrophin receptor, p75NTR, has been implicated in diverse responses 
of sensory neurons including a role in nociception following nerve injury, suggesting that it may 
serve a similar role in intact sensory neurons and their satellite glial cells (SGCs).  To examine 
the impact of suppressing neuronal p75NTR expression on known molecular 
modulators/regulators of the nociceptive state namely, the sodium channels NaV1.8 and NaV1.9, 
the nerve growth factor receptor TrkA, the potassium channel Kir4.1, glial fibrillary acidic 
protein (GFAP), SGC p75NTR, connexin 43, we intrathecally infused p75NTR anti-sense 
oligonucleotides (AS OGN), previously shown by Obata et al. (2006) to effectively suppress 
p75NTR expression in intact neurons. Male, Wistar rats were divided into three groups, 
receiving either no treatment (non-infused), seven day intrathecal infusion of p75NTR AS OGN 
or sense control (SC OGN) via an osmotic pump.  Serial L4 and L5 DRG sections were 
processed for immunohistochemistry to detect alterations in NaV1.8, NaV1.9, TrkA, Kir4.1, 
p75NTR, GFAP and connexin-43 protein expression. Sciatic nerve sections were also processed 
for immunohistochemistry to detect NaV1.8, NaV1.9, TrkA and GFAP protein expression. 
Infusion of p75NTR AS OGNs resulted in a significant decrease in neuronal p75NTR 
expression, however no significant change was observed in neuronal NaV1.8, NaV1.9 or TrkA 
expression relative to SC OGN treated or non-infused controls.  On the contrary, SGC expression 
of phenotypic markers normally associated with the reactive state that is induced in these cells in 
response to peripheral nerve axotomy was dramatically altered.  More specifically, in response to 
p75NTR AS OGN infusion, there was a significant increase in SGC protein expression of the 
cytoskeletal protein GFAP and p75NTR, along with a significant decrease in expression of the 
inward rectifying potassium channel Kir4.1.  Preliminary data also revealed this induced reactive 
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state in SGCs to be associated with an increase in the number of SGCs surrounding individual 
neurons as well as increased SGC expression of the gap junction protein, connexin 43. 
In conclusion, reductions in neuronal p75NTR expression and potentially reduced 
neurotrophin signaling lead to alterations in neuron/glial or axon/glial communication that results 
in induction of a reactive phenotype in the associated SGCs.  With our ever increasing 
understanding of the role of SGCs modulating pain states, elucidation of the pathways leading to 
adoption of pathological phenotypes can help in the identification of novel therapeutic targets.   
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1. Introduction 
Neuropathic pain is a syndrome characterized by chronic spontaneous aberrant 
neural firing of sensory neurons in the absence of noxious stimuli.  This can include 
amplification of sensation to mechanical stimuli (mechanical allodynia) where input 
previously perceived as nonnoxious is now noxious and reduced thresholds for thermal 
stimuli (thermal hyperalgesia).  Thus, warmth, cold, light touch or no sensation at all, 
may be perceived as painful. 
In contrast to acute pain that is effectively treated with general analgesics such as 
opioids, chronic pain is difficult to treat.  Current therapies for chronic pain are not 
adequate and include antidepressants, non-steroidal anti-inflammatory drugs (NSAIDs) 
and potent opioids. The plethora of treatment options stems mostly from the poorly 
understood etiology of the neuropathic pain state and the lack of specific drug targets 
(reviewed in Chen et al., 2004).  Elucidating the underlying anatomical, morphological 
and chemical changes that cause nerves to transition from normal baseline functioning to 
anomalous, hypersensitive malfunction is of paramount importance.  Until these are 
elucidated, nonspecific systemic treatments that only slightly mitigate the pain syndrome 
will continue to be used. 
 
1.1 Pain 
Pain occurs in response to noxious stimuli.  It encourages the organism to 
withdraw from a sensory experience, to protect damaged tissue and to learn what harmful 
situations to avoid in the future.  It is considered essential to the survival of an organism; 
individuals with congenital insensitivity to pain usually do not live past childhood 
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(reviewed in Nagasako et al., 2003).  Without the sensation of pain, young children will 
chew on their own tongue, lips, fingers and will often not be aware of having experienced 
serious injuries.  Some of these genetic mutations are associated with voltage-gated Na+ 
ionic channels responsible for propagating action potentials in sensory neurons (reviewed 
in Lampert et al., 2010).  When excessive chemical, mechanical or thermal stimuli are 
applied to tissue, nociceptive nerve fibers experience a depolarization that initiates action 
potentials.  
Neuropathic pain results from a direct or indirect injury to the nervous system and 
has been described as ‘bad pain’ as it does not promote the survival of the organism 
(reviewed in Iadarola and Caudle, 1997). The nerve fibers are thus inflamed, 
dysfunctional or injured and correspondingly do not depolarize and propagate action 
potentials within normal baseline parameters.  Injuries to the nerves may occur, for 
example, as a result of a trauma, infection or as a secondary etiology to many diseases 
including alcoholism, diabetes, human immunodeficiency virus, multiple sclerosis or 
herpes zoster (shingles). The symptoms are often described as shooting/burning or as 
tingling/numbness.  These sensations may occur more frequently than normal or may be 
prolonged due to altered thresholds for stimulation.  Eventually, they may occur 
spontaneously in the absence of stimuli.  This altered sensitivity characteristic of 
neuropathic pain is associated with changes in cell morphology, membrane ion channels 
such as voltage-gated sodium channels or potassium channels, receptors, proteins, 
neurotrophins and many other factors. 
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1.2 Introduction to the nervous system 
 The nervous system is a complex network of specialized cells and supporting 
elements that effectively and efficiently transmit signals across parts of the body.  These 
signals are conveyed via action potentials established by ionic gradients across the 
neuronal membrane.  The central nervous system consists of the brain and spinal cord 
and the peripheral nervous system includes the cranial nerves and spinal nerves.  The 
perception of one’s environment relies directly on the afferent component of the nervous 
system, the sensory system.  The somato-sensory system is charged with relaying a 
variety of sensations such as proprioception, mechanoception and nociception and thus, 
consists of a variety of neurons.  The cell bodies of these neurons are situated in 
structures located just outside the spinal cord parenchyma called the dorsal root ganglia 
(DRG) (See Figure 1.1).  A single pseudounipolar process extends from the cell body of 
each neuron, and this branches into two axonal processes: one projects distally to the 
peripheral tissues and the other branches centrally to terminate within the dorsal horn of 
the spinal cord or within the brainstem nuclei via the dorsal columns.  Sensory 
information is consequently transmitted from the peripheral tissues to the brainstem and 
then onwards to the thalamus, cerebellum and cerebral cortex.  This directly influences 
both an organism’s perception and response to external stimuli (reviewed in Kandel et al., 
2000).   
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Figure 1.1 The dorsal root ganglia.  Sensory information from the peripheral nervous 
system inputs into the spinal cord. Sensory afferents in the dorsal roots enter into the 
dorsal/posterior side of the spinal cord, with the pain fibers largely terminating in the 
region referred to as the dorsal horns, while the motor neuron efferents housed in the 
region known as the ventral horn, exit the spinal cord on the ventral/anterior side via the 
ventral roots.  The cell bodies of the sensory nerves are located in a structure, just outside 
the spinal cord, known as the dorsal root ganglion. 	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1.3 Sensory neurons 
1.3.1 Anatomic and physiological properties 
 The somato-sensory system is comprised of subpopulations of neurons that 
express different receptors in order to be activated by different types of stimuli.  Thus, 
sensory neurons are commonly classified by the type of stimulus that activates them: 	  
proprioceptive, mechanoreceptive or nociceptive. These three types of neurons have 
significantly different conduction velocities of their action potentials owing to different 
axonal properties (reviewed in Millan, 1999; Villiere and McLachlan, 1996).  
Proprioceptive neurons’ axons are known as A-α fibers, are large in diameter (12-20 
µm), are highly myelinated and have a conduction velocity of 70-120 m/s. 
Mechanoreceptive neurons’ axons known as A-β fibers, are medium in diameter (5-15 
µm), are myelinated and have a conduction velocity of 30-80 m/s. Lastly, nociceptive 
neurons’ axons can be subdivided into two groups: the first are known as A-δ  fibers, are 
small in diameter (3-8 µm), are myelinated and have a conduction velocity of 10-30 m/s 
and the second, known as C fibers, are very small in diameter (0.2-1.5 µm), are 
unmyelinated and have a conduction velocity of 0.5-2.5 m/s.   The cell bodies of the 
sensory neurons are mostly aggregated along the periphery of the DRG structure with 
their processes located more medially.  In parallel with the diameters of their axons, the 
cell bodies of the various sensory neurons can roughly be separated by their diameters: 
proprioceptive neurons are ~40-80 µm, mechanoreceptive are ~25-40 µm and nociceptive 
neurons are ~10-25 µm, with some overlap between the three (Crowley et al., 1994; 
Smeyne et al., 1994).  For example, there are some small-medium sized cells that are low 
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threshold mechanoreceptors and some medium-large cells that are nociceptors (Djouhri et 
al., 2003b; Fang et al., 2002). 
 
1.3.2 Associated glia and sensory neuron/glial communication 
The peripheral nervous system contains two well-known types of glial cells, 
Schwann cells and perineuronal satellite glial cells (SGCs), and a few poorly 
characterized cells that resemble microglia and less differentiated Schwann cells.  A large 
portion of the Schwann cells envelops the axons of the majority of neurons, producing an 
insulating protein called myelin, which increases the conduction velocity of action 
potentials.  The SGCs, initially described and somewhat dismissed as a type of Schwann 
cell, are actually very unique from other glial cells in terms of both their development and 
the functional structure they form.  Multiple SGCs encapsulate the cell body of each 
sensory neuron within the DRG structure, forming a cellular envelope (reviewed in 
Hanani, 2005; Pannese, 1981 see Figure 1.2).  The barrier they form, usually one to three 
layers thick (Pannese, 1960), allows for the diffusion of most molecules (Shinder and 
Devor, 1994), unlike the blood brain barrier, but helps to maintain a homeostatic 
environment necessary for the passing of action potentials in the sensory neurons 
(reviewed in Hanani, 2005).  This role appears to be vital as cross excitation of action 
potentials occurring across the DRG because of neural apposition is unlikely because, 
once matured, less than 2% of neurons are closely apposed (Shinder et al., 1998). 
Therefore, this substantiates that SGCs may be responsible for propagating excitability in 
the DRG.  Moreover, SGCs contribute to the neuronal homeostatic environment by 	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Figure 1.2 Sensory neuron and satellite glial cells.  The sensory neuron is pseudo-
unipolar in structure.  One apparent process extends from the cell body and then branches 
into the peripheral axon that projects to the periphery of the body and the central axon 
that projects to the spinal cord and central nervous system. Some of these sensory 
neurons have myelinated axons (as shown above) and others have unmyelinated axons 
and are referred to as C-fibers. All of the sensory neuron cell bodies are encapsulated by 
supporting glials cell unique to the peripheral nervous system, the satellite glial cells 
(SGCs).	  	  	  	  	  	  
	   8	  
taking up and degrading neurotransmitters (Braun et al., 2004; Keast and Stephensen, 
2000).  
  
1.4 Role of neurotrophins in sensory neurons and associated glia with relation to 
neuropathic pain states 
1.4.1 Members of the neurotrophin family 
Neurotrophins in the peripheral nervous system modulate and regulate the 
survival, differentiation, and maintenance of neurons and glia.  The mammalian family of 
neurotrophins consists of nerve growth factor (NGF), brain-derived nerve growth factor 
(BDNF), neurotrophin-3 (NT-3) and neurotrophin-4/5 (NT-4/5).  They bind to the 
tropomyosin-related kinase receptors (Trk) and/or the common neurotrophin receptor, 
p75NTR (See Figure 1.3), are taken up axonally and transported retrogradely to the cell 
bodies of the sensory neurons (Curtis et al., 1995).  All of the neurotrophins have 
approximately 50% amino acid homology between them, share similar three-dimensional 
conformation and are seen as homodimers in their active state.  Because of a highly 
lipophilic center region within the neurotrophins, they are thus capable of forming 
heterodimers with other neurotrophins (Robinson et al., 1995), although any role for this 
remains to be elucidated in vivo.   
Glial derived neurotrophic factor (GDNF), a member of the transforming growth 
factor β family, also has trophic effects on sensory neurons, despite being structurally 
different from the neurotrophin family, being in a class of its own.  It acts primarily on 
the ~20% of primarily small sensory neurons that do not express neurotrophin receptors 
and are often referred to as nonpeptidergic (Henderson et al., 1994; Trupp et al., 1995). 
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Figure 1.3 Neurotrophin and neurotrophin receptor interactions.  Neurotrophins in 
the peripheral nervous system modulate and regulate the survival, differentiation, and 
maintenance of neurons and glia.  The mammalian family of neurotrophins consists of 
nerve growth factor (NGF), brain-derived nerve growth factor (BDNF), neurotrophin-3 
(NT-3) and neurotrophin-4/5 (NT-4/5).  They bind to the tropomyosin-related kinase 
receptors (Trk) with higher affinity (solid arrows) and/or the common neurotrophin 
receptor, p75NTR, with lower affinity (dashed arrows).  NGF binds to TrkA, NT-3 
preferentially binds to TrkC but can also bind to TrkA and TrkB, while BDNF and NT-
4/5 both bind to TrkB. 	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NGF was the first neurotrophin to be identified back in the early 1950’s by Rita 
Levi-Montalcini and Viktor Hamburger.  It is a 26-kDa nonglycosylated, homodimeric 
polypeptide and was given its name by Cohen in 1954.  It was initially observed in mouse 
sarcomas and later on in snake venom and the submaxillary glands of mice (Cohen and 
Levi-Montalcini, 1956; Levi-Montalcini and Cohen, 1960; Levi-Montalcini and 
Hamburger, 1951).  They described it as a growth factor necessary for the survival and 
outgrowth of sensory and sympathetic neurons but not motor neurons (Levi-Montalcini 
and Hamburger, 1951).  NGF’s primary receptor is TrkA located on small nociceptive 
neurons and p75NTR (Crowley et al., 1994; Kaplan et al., 1991; Smeyne et al., 1994; 
Squinto et al., 1991). 
BDNF was initially identified in 1982 by Barde et al.  It was discovered in 1989 
that BDNF was structurally similar to NGF (Leibrock et al., 1989).  BDNF binds to TrkB 
receptors located on the medium sized mechanoreceptive neurons and p75NTR (Klein et 
al., 1991; Mu et al., 1993; Schecterson and Bothwell, 1992; Snider and Wright, 1996; 
Squinto et al., 1991).   
NT-3 was later identified using homology-based approaches to find factors 
similar to NGF and BDNF (Hohn et al., 1990; Maisonpierre et al., 1990).  NT-3 binds 
preferentially to TrkC receptors located on the large proprioceptive neurons as well as 
p75NTR (Farinas et al., 1994; Lamballe et al., 1991; Mu et al., 1993; Squinto et al., 
1991).  It has also been shown that NT-3 can also bind to TrkA and TrkB albeit with a 
lower affinity than their higher affinity binding neurotrophins, NGF and BDNF 
respectively (Ip et al., 1993; Ivanisevic et al., 2007; Klein et al., 1991). 
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NT-4 was first isolated from a xenopus and a viper (Hallbook et al., 1991) and 
NT-5 from the placenta of a human fetus (Berkemeier et al., 1991). It was later 
discovered that they are two different species variations of the same neurotrophin now 
commonly referred to as NT-4/5.  NT-4/5 like BDNF, binds to TrkB receptors located on 
the medium sized mechanoreceptive neurons that also express p75NTR (Berkemeier et 
al., 1991). 
GDNF was first purified in 1993 and it was initially believed that it was a survival 
factor for only dopaminergic neurons (Lin et al., 1993).  GDNF has a strong trophic 
effect on Schwann cells and sensory neurons (Matheson et al., 1997; Naveilhan et al., 
1997).   
 
1.4.2 Sources of neurotrophins for sensory neurons 
NGF, NT-3, NT-4/5 and GDNF are derived from the sensory neurons’ effector 
tissues and following binding to, and internalization with their high-affinity Trk receptor, 
travel to the somata via retrograde transport (Cui et al., 2007; Curtis et al., 1995; Helgren 
et al., 1997; Ibanez et al., 1993; Matheson et al., 1997; Timmusk et al., 1993).  Unlike the 
other neurotrophins, BDNF is synthesized by some of the DRG neurons.  In the intact 
axonal state, its expression is primarily localized to the small, TrkA expressing, 
nociceptive population of neurons in the DRG (Karchewski et al., 2002).  The SGCs, 
surrounding the neuronal cell bodies, actually synthesize low levels of NGF, NT-3 and 
GDNF themselves (Hammarberg et al., 1996; Zhou et al., 1999).  Finally, nerve-derived 
Schwann cells also produce low levels of NGF, BDNF, NT-3, NT-4/5 and GDNF 
(Hammarberg et al., 1996; Meyer et al., 1992; Ming et al., 1999; Saika et al., 1991; Watabe 
et al., 1995). 
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1.4.3 Members of the neurotrophin receptor family 
All of the neurotrophins bind to two types of receptors: members of the Trk 
family of receptor tyrosine kinases and the common neurotrophin receptor, p75NTR.  
There are three mammalian Trk (tropomyosin-related kinase) receptors: TrkA, TrkB and 
TrkC.  They are transmembrane glycoproteins approximately 140 kD in size (~800 amino 
acids) (Schneider and Schweiger, 1991) and their functions range from regulating the 
development, differentiation and survival of neurons to modulating synapse formation 
and plasticity.  There is an approximate 80% amino acid homology in the intracellular 
tyrosine kinase domains between the Trk receptors and much less in their extracellular 
domains (approximately 30%) despite having the same subdomain organization with five 
components: two cysteine-rich motifs, a leucine-rich motif and immunoglobulin-like 
subdomains Ig-C1 and Ig-C2 (reviewed in Bibel and Barde, 2000).  The low homology of 
the extracellular domains accounts for the specificity and selectivity of the Trk receptors 
for their ligands.  Specific tyrosine residues within the intracellular domains of the Trk 
receptors can be phosphorylated when neurotrophins bind to the extracellular domain, 
forming an activation site and allowing for the binding of adaptor proteins (Kaplan and 
Stephens, 1994).  
P75NTR is a member of the tumour necrosis factor receptor family was named as 
such because of its 75 kDa size (399 amino acids) (Chen et al., 2009). Although it was 
identified 20 years ago, p75NTR’s exact physiological functions are not completely 
understood.  The neurotrophins all bind to p75NTR with less affinity (~10-9 M) than the 
family of Trk receptors (~10-11 M) (Rodriguez-Tebar et al., 1990; Rodriguez-Tebar et al., 
1992).  Despite the similarity in their nanomolar affinity to p75NTR, each neurotrophin 
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appears to target different residues; each producing different conformational changes 
(Timm et al., 1994).  In addition to signaling independent of the Trk receptors, 
experimental evidence has implicated p75NTR in regulating Trk signaling (Benedetti et 
al., 1993; Hempstead et al., 1991; Maliartchouk and Saragovi, 1997).  It is believed that 
these two classes of receptors also exist as one functional unit.  P75NTR appears to alter 
the sub domain of the Trk receptors to reveal an additional binding site for neurotrophins 
as evidenced by Zaccaro et al. (2001) observing a 10-9 M to 10-11 M binding affinity 
increase.  For example, TrkC contains a NT-3 binding site that is functionally regulated 
by p75NTR expression that when activated induces survival but not differentiation 
(Ivanisevic et al., 2003). The ratio of TrkA to p75NTR appears to be the key in 
modulating binding affinity and the overall effects of NGF and NT-3 to either of these 
receptors (Brennan et al., 1999). The TrkA to p75NTR ratio also regulates their own 
internalization/mobilization rates to the membrane (Makkerh et al., 2005). 
 
1.4.4 Distribution of neurotrophin receptors in sensory ganglia 
 There exist multiple isoforms of each of the three Trk receptors.  TrkB and TrkC 
are found as either full length or as truncated variants that lack the intracellular tyrosine 
kinase domain (Klein et al., 1990; Lamballe et al., 1993).   
The TrkA receptor is a high-affinity catalytic receptor whose main ligand is NGF 
and has been identified in ~40-45% of sensory neurons in the lumbar DRG by the 
presence of its messenger ribonucleic acid (mRNA) that colocalizes with the presence of 
NGF high-affinity binding sites (Kaplan et al., 1991; Karchewski et al., 1999).  
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Approximately 89% of TrkA positive neurons are small/medium in size (less than 40 µm 
in diameter), while the remainder is classified as large (Karchewski et al., 1999). 
The TrkB receptor is a high-affinity catalytic receptor whose ligands are BDNF 
and NT-4/5 and  ~33% of lumbar sensory neurons express its mRNA above detection 
levels (Karchewski et al., 1999; Klein et al., 1991; Squinto et al., 1991).  The majority, 
~90%, of TrkB positive sensory neurons are medium/large in diameter (Karchewski et 
al., 1999). 
The TrkC receptor is a high affinity catalytic receptor whose ligand is NT-3 and 
its mRNA has been localized to ~43% of the lumbar sensory neuron population 
(Karchewski et al., 1999; Lamballe et al., 1991).  Of those positive for TrkC, 85% of 
them are medium/large in diameter (Karchewski et al., 1999). 
Evidently, given the percentages of the sensory neuron population positive for the 
three Trk receptors, some colocalization and trilocalization must exist.  It was reported 
that ~10% coexpress TrkA and TrkB mRNA, ~19% coexpress TrkA and TrkC mRNA, 
~18% coexpress TrkB and TrkC and only ~3-4% express all three mRNAs (Karchewski 
et al., 1999).  Truncated forms of TrkB and TrkC, lacking their intracellular catalytic 
domains, exist in both the central and peripheral nervous systems whose functions are 
both poorly understood (Klein et al., 1990; Valenzuela et al., 1993).  
Approximately 79% of DRG neurons express p75NTR.  This expression is across 
all size ranges and is almost always accompanied by some level of Trk receptor 
expression (Karchewski et al., 1999).  It is highly colocalized with TrkA and positively 
correlates with the level of TrkA expression (Verge et al., 1992).  However, Wright and 
Snider did not find strong colocalization of p75NTR with all Trk subpopulations as only 
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8% of TrkB positive sensory neurons express detectable p75NTR mRNA and only about 
50% of the TrkCs appeared to do so (Verge et al., 1992; Wright and Snider, 1995).  Their 
lower percentage of overall Trk and p75NTR expression relative to that of the Verge lab 
(Karchewski et al., 1999) suggest that it may be due to the sensitivity of the technique 
employed.  In addition to neuronal expression, SGCs and Schwann cells are found to 
express p75NTR (Gai et al., 1996; Zhou et al., 1996). 
Distinct from the Trk expressing subpopulations is a population of sensory 
neurons that do not bind any of the neurotrophins (do not express detectable Trk or 
p75NTR mRNA), are small/medium in diameter and represent ~20% of sensory neurons 
(Karchewski et al., 1999).  These neurons express the GDNF receptor, which is 
composed of a ligand-binding subunit known as GDNF receptor α and a signaling 
tyrosine kinase subunit Ret.  The ability to bind isolectin from griffonia simplicifolia 
(IB4) is also another distinguishing characteristic of this subpopulation (Bennett et al., 
1998).  
 
1.4.5 Regulation of pain states by neurotrophins 
 Neuropathic pain states result from two very distinct nerve injuries: 
compression/constriction and partial nerve severance resulting in inflammation  (referred 
to as a nerve lesion) or complete nerve severance/axotomy (referred to as an axotomy).  
The type of injury can differentially affect the neurotrophin/neurotrophin receptor levels 
within both the sensory neuron subpopulations and the glial cells within the peripheral 
nervous system.  
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NGF is involved in neuropathic inflammation-associated pain in that it activates 
the TrkA receptor on nociceptive neurons, modulating signaling and gene expression, 
promoting hypersensitivity to mechanical and/or thermal stimuli (Jongsma Wallin et al., 
2001; Jongsma Wallin et al., 2003; Verge et al., 1995; Verge et al., 1990).  A partial 
nerve lesion upregulates NGF and this leads to the activation and upregulation of 
receptors including transient receptor potential vanilloid receptor-1 (TRPV1), directly 
associated with the activation of nociceptive/thermoreceptive sensory neurons (Garcia-
Martinez et al., 2002; Ji et al., 2002).  Expression of NGF in SGCs increases significantly 
in the DRG corresponding to a nerve lesion but is still not sufficient to reverse the injury 
phenotype that appears due to the far more substantial loss of target-derived NGF (Zhou 
et al., 1999).  
BDNF expression rises sharply in ~80% of sensory neurons following a nerve 
lesion, followed by a reduction in expression in the small, TrkA expressing nociceptive 
population and an induction in the medium to large, TrkB and/or TrkC expressing 
population (Karchewski et al., 2002).  This phenotypic switch is believed to be necessary 
in initiating repair programs including remyelination of the nerves.  BDNF has been 
shown to promote myelination during both development and after an injury via the 
p75NTR present in sensory neurons and Schwann cells in vitro and in vivo (Chan et al., 
2001; Cosgaya et al., 2002; Zhang et al., 2000).   
 NT-3 has recently been linked to the nociceptive subpopulation of neurons in that 
it affects a downregulation in the expression of nociception-associated molecules in 
TrkA-expressing neurons, including that of TrkA.  In the injured/inflamed state 
associated with a chronic constriction injury (CCI) of the nerve where only some of the 
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nerve fibers are injured, NT-3 can prevent or reverse thermal hypersensitivity and 
downregulate expression of molecules complicit in this behavior, in contrast to NGF 
(Gratto and Verge, 2003; Jongsma Wallin et al., 2001; Karchewski et al., 2002; Verge et 
al., 1996; Wilson-Gerwing et al., 2005).  However, no changes in mechanical 
hypersensitivity were observed with the infusion of NT-3 following a nerve lesion, 
specifically a CCI (Wilson-Gerwing et al., 2005).  In the non-injured/intact state, NT-3 
has been shown to downregulate markers associated with nociceptive phenotype 
including TrkA, voltage-gated Na+ channels 1.8 and 1.9 (NaV1.8 and NaV1.9), TRPV1 
and activated p38 mitogen-activated protein kinase albeit to a far less degree compared to 
that observed in the CCI state (Gratto and Verge, 2003; Wilson-Gerwing et al., 2005; 
Wilson-Gerwing et al., 2009).  Of note, in the uninjured state, NT-3 fails to affect thermal 
and/or mechanical thresholds (Wilson-Gerwing et al., 2005).  Expression of NT-3 in 
SGCs increases significantly in the DRG corresponding to a nerve lesion but it is not 
known if this source results in a direct modulation of the nociceptive phenotype (Zhou et 
al., 1999). 
 Currently, NT-4/5’s role in neuropathic pain states is poorly understood.  Its 
effects are seemingly in parallel to that of BDNF; its injection, or that of BDNF, into the 
rat hind paw significantly decreased thermal stimulation threshold (Shu et al., 1999).  It 
has been linked to regeneration; NT-4/5 knockout mice were shown to have no 
enhancement of axonal regeneration with electrical stimulation as compared to wild type 
mice (English et al., 2007).  
GDNF mRNA expression in Schwann cells and SGCs is rapidly upregulated 
following a nerve injury (Hammarberg et al., 1996). The distal portion of the injured 
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nerve but not the proximal section or spinal cord expressed higher levels of GDNF-α 
receptor mRNA.  As with NGF and NT-3 (see above) the increased levels of SGC GDNF 
expression albeit higher, were not sufficient to reverse the injury-induced alteration in 
neuronal phenotype for this subpopulation – i.e. the decreased IB4 binding (Bennett et 
al., 1998). 
 
1.4.5.1 Alterations in neurotrophin receptor expression 
 In parallel with neurotrophin expression levels varying with injury type, 
neurotrophin receptor expression levels can also be differentially affected by either a 
partial nerve lesion or complete axotomy.  Following a three week lumbar spinal nerve 
injury, the number of NGF high-affinity binding sites falls drastically, by more than 80% 
and include a parallel decrease in TrkA and p75NTR mRNA expression (Verge et al., 
1989), with mRNA expression levels being 55% below normal levels two weeks post-
injury in response to ligation injury (Kuo et al., 2007).  With a partial nerve lesion such as 
a CCI, where only the outside axons are injured leaving the axons in the middle of the 
nerve intact but exposed to an inflammatory environment, there is a no consistent impact 
in TrkA expression (Wilson-Gerwing and Verge, 2006).  Similar responses with respect 
to neuronal p75NTR expression were observed by Karchewski et al. (2002) and Kuo et 
al. (2007) in response to lumbar spinal nerve transection or sciatic nerve ligation injury.  
In regards to spinal nerve injury-induced downregulation of NGF TrkA and p75NTR 
receptor expression, this is likely due to the marked decrease in axonal NGF transport 
from the peripheral effector/target tissues.  This is supported by the ability of 
intrathecally infused NGF to restore NGF TrkA and p75NTR receptor expression to near 
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pre-injury levels in the chronically injured neurons (Li et al., 2000).  The situation is 
different in the case of a CCI, where the Wallerian-degenerating injured fibers invoke 
increased expression of NGF in the nerve.  As is seen with other partial nerve injury 
models, the exposure of these uninjured fibers to this inflammatory environment results 
in increased expression of nociception-associated molecules and instatement of a 
neuropathic pain state.  This is driven largely by NGF influences on these uninjured 
neurons that are both still connected to an abundant source of NGF in the target tissue 
and exposed to additional NGF at the site of injury (Fukuoka et al., 2001; Herzberg et al., 
1997; Ma and Bisby, 1998; Ma et al., 2010).  While not extensively studied, the Verge 
lab did not note declines in neuronal p75NTR mRNA expression when utilizing the 
partial nerve injury model CCI (Wilson-Gerwing et al., 2008). 
 The receptor for BDNF and NT4-5, full length TrkB, can be detected in 
approximately 33% of adult sensory neurons (Karchewski et al., 1999).  In response to 
lumbar spinal nerve lesion and sciatic nerve injuries, declines in neuronal full length 
TrkB mRNA expression is evident at time points beyond one day.  The slight increase 
observed at the one day time point is perhaps due to the rapid and transient increase in 
DRG BDNF expression that is seen at very early time points (Karchewski et al., 2002; 
Kuo et al., 2007; Obata et al., 2006).  
  Finally, full length TrkC mRNA is expressed by ~40-45% of DRG neurons 
(Karchewski et al., 1999).  There is discrepancy in how its neuronal expression is altered 
by nerve injury.  The Verge lab observes consistent declines in TrkC expression with 
spinal nerve injury.  This is also observed at the five day injury time point by Obata et al. 
(2006).  This can be reversed in the chronically injured neurons, along with the associated 
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changes in expression of phenotypic markers for this subpopulation by infusion of 
exogenous NT-3 two weeks after injury for a one week period (Jongsma Wallin et al., 
2001; Karchewski et al., 2002; Verge et al., 1996).  As is the case for TrkA, this suggests 
that disconnection of the axon from target –derived sources of NT-3, likely accounts for 
the decline in TrkC expression observed following spinal nerve transection and alteration 
in phenotype observed.  These findings are in contrast with those of Kuo et al. (2007), 
where a notable and sustained increase in TrkC expression was observed in response to 
sciatic nerve ligation and transection.  How the CCI partial nerve injury impacts TrkC 
expression has not been studied. 
 
1.4.5.2 Alterations in neuronal properties associated with injury/pain states 
Maintenance of receptor and channel homeostasis within the neuronal membrane 
of the sensory system is essential for the proper transmission of proprioceptive, 
mechanoreceptive or nociceptive information. The ionic gradient necessary for 
establishing the action potential threshold across the neuronal membrane of nociceptive 
neurons is reliant on Na+ channels 1.8 and 1.9. 
Expression of the Na+ channel NaV1.8 appears to be exclusive to the sensory 
system and specifically localized to the smaller, nociceptive DRG neurons (Djouhri et al., 
2003a).  Sixty percent of neurons that express NaV1.8 also bind the isolectin griffonia 
simplicifolia (IB4) (that identifies a subpopulation of sensory neurons that is 
predominantly GDNF-responsive with little or no detectable Trk or p75NTR expression) 
(Fukuoka et al., 2008) and thus, correspondingly, almost all of the remaining 40% also 
express p75NTR (Wright and Snider, 1995).  NaV1.8 channels are responsible for the 
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majority of the action potentials and significant changes in their expression levels are 
believed to contribute to the altered neuronal excitability, playing a role in the aberrant 
action potential firing experienced leading to chronic pain (Blair and Bean, 2002; Lai et 
al., 2004; Waxman et al., 1999).  It appears that NaV1.8 levels may decrease in the 
directly injured nerves, small diameter neurons, however, the uninjured adjacent DRG 
neurons and their axons have increased expression of NaV1.8 and it may contribute to the 
aberrant action potential activity seen following nerve lesion (Wang et al., 2011). 	  
NaV1.9 is expressed in pain-signalling, smaller DRG neurons (Wang et al., 2011). 
Within the DRG, 62% of neurons that express NaV1.9 are also IB4-positive (Fukuoka et 
al., 2008).  Clinically, the use of Na+ channel blockers such as Lidocaine® have been 
shown to provide some relief of neuropathic pain syndromes (Priest and Kaczorowski, 
2007).  
NaV1.9 channels are also highly colocalized with TRPV1 and purinergic P2X3 
receptors (Amaya et al., 2006).  These receptors are directly associated with the 
activation of pain sensations.  TRPV1 is highly expressed in both the Trk-A positive 
subpopulation and the IB4 positive subpopulation of the DRG (Helliwell et al., 1998; 
Michael and Priestley, 1999) and is activated by heat greater than 43 oC, low pH, 
exogenous compounds including capsaicin associated with spiciness from chili peppers 
and venoms from jellyfish and spiders, as well as endogenous compounds NGF and 
anandamide (reviewed in Clapham et al., 2005; Szallasi et al., 2007).  The P2X3 receptor 
is an ATP specific ligand-gated ion channel and exists as a homomeric form, P2X3, 
localized to smaller DRG neurons and as a heteromeric form, P2X2/3, localized to 
medium-large DRG neurons (Kage et al., 2002).  The activation of P2X3 is believed to 
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contribute to acute nociception.  It is downregulated in damaged peripheral nerves and 
upregulated in the adjacent uninjured nerves with a partial nerve injury (Tsuzuki et al., 
2001) and it is downregulated with an axotomy (Bradbury et al., 1998).  On the other 
hand, the activation of P2X2/3 is believed to drive longer-lasting nociception as its levels 
within the DRG are not altered following nerve ligation (Kage et al., 2002). 
 
1.4.5.3 Alterations in perineuronal cell phenotype associated with injury/pain states 
Glial cells within the central and peripheral nervous systems are associated with 
maintaining neuronal homeostatic function of the neuronal network.  With injury, these 
glial cells may contribute to the production and the development of chronic pain.  In the 
case of peripheral nerve injuries, the SGCs, unique to the sensory and autonomic systems, 
are optimally positioned to affect neuronal excitability, tightly surrounding the cell bodies 
of the sensory neurons within the dorsal root ganglia.  With injury, SGCs become highly 
activated, proliferate and have increased coupling amongst themselves (Dublin and 
Hanani, 2007; Lu and Richardson, 1991). They correspondingly have increased 
expression of glial fibrillary acidic protein (GFAP), p75NTR, GDNF, NGF, NT-3, 
connexin 43, a gap junction protein, and decreased expression of inward rectifying K+ 
channel 1.4 (Kir4.1) (Guo et al., 2007; Ohara et al., 2008; Tang et al., 2010; Xian and 
Zhou, 1999; Zhou et al., 1996).  Schwann cells also contribute to regeneration following 
an injury by migrating across the nerve gap, forming a continuous structure to guide 
axonal regrowth (Torigoe et al., 1996). 
GFAP is the predominant constituent of the cytoskeleton of many glial cells.  It is 
an intermediate filament protein and is believed to contribute to the mechanical strength 
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of the cells, helping to maintain their shape.  It has long been established in astrocytes of 
the central nervous system, however it was only identified in 1984 by Jessen et al. in 
Schwann cells and satellite cells in both the sensory and autonomic ganglia of the 
peripheral nervous system.  Increased GFAP expression is commonly associated with a 
transition to a ‘reactive state’ of the glial cells in question.  In the DRG, SGCs express 
very low levels of GFAP under normal conditions (Vit et al., 2006).  Following an injury 
or chronic inflammation, GFAP levels steadily increase until most SGCs are GFAP 
immunoreactive (Siemionow et al., 2009).  An increase in fibrils within the cytoplasm of 
SGCs following nerve injury had been described as long ago as 1967 by Leech. 
After a chemical or mechanical insult, it has been reported that SGCs surrounding 
sensory neurons undergo division and proliferate as evidenced by an increased 
concentration of mitotic figures observed at the electron microscope level (Hiura and 
Ishizuka, 1989; Humbertson et al., 1969) and the presence of BrdU positive cells 
surrounding the sensory neuron cell bodies (Cecchini et al., 1999; Elson et al., 2004; 
Elson et al., 2003).  In addition to a proliferation in the number of SGCs after a nerve 
injury, SGCs are also more coupled amongst themselves, postulated to be a result of an 
increase in gap junction concentration (Ledda et al., 2009; Zhang et al., 2009).  Connexin 
43 is a subunit of gap junctions in SGCs, and is not found in the sensory neurons (Ohara 
et al., 2008).  Functionally, gap junctions are involved in the diffusion of ionic currents, 
including K+, amongst SGCs (Huang et al., 2005; Konishi, 1996).  Thus, connexin 43 
expression levels indirectly affect neuronal excitability.  The extent of their influence on 
neuronal function was demonstrated by Vit et al. (2006) by introducing RNA interference 
specific to connexin 43 to the trigeminal ganglion in rats. This resulted in the 
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development of spontaneous pain-like behaviour and the return of connexin 43 
expression to baseline levels subsequently restored normal behaviour. 
Kir4.1 is highly expressed in glial cells of the central nervous system.  It was 
recently reported that it is also highly expressed in SGCs (Vit et al., 2006).  It is believed 
that these channels contribute to the hyperpolarized resting membrane potential of SGCs 
and help regulate the conductory extracellular K+ levels (Kofuji and Newman, 2004; 
Olsen and Sontheimer, 2008).  These roles are considered vital as buffering is necessary 
to maintain optimal extracellular K+ levels for neuronal activity (Kofuji and Newman, 
2004).  Kir4.1 has recently been inversely associated with neuropathic pain.  SGCs post-
injury have a lower expression of Kir4.1 compared to pre-injury levels (Ohara et al., 
2009).  For example, a chronic constriction injury of the trigeminal nerve, a model of 
facial pain, resulted in downregulation of Kir4.1 levels in trigeminal SGCs.  By 
decreasing Kir4.1 expression in rat trigeminal SGCs with small interfering RNAs, facial 
neuropathic pain-like behaviours were observed by both Ohara et al. (2008) and Vit et al. 
(2008).  These robust findings are not surprising given that the Kir4.1 channel appears to 
be the principal regulator of SGC K+ levels.  The partial and complete genetic ablation of 
the Kir4.1 gene lead to a halving and almost complete loss of the inward K+ respectively 
(Tang et al., 2010). 
 
1.4.5.4 Involvement of the common neurotrophin receptor, p75NTR, in neuropathic 
pain states 
Within the organism, expression levels of p75NTR tend to be high during 
development, taper during adulthood and increase dramatically during pathological states 
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(Chao, 2003).  In terms of the sensory neuron populations, after a nerve axotomy, 
p75NTR is dramatically downregulated.  This reduction can be reversed with the infusion 
of NGF, however only in the subpopulation expressing TrkA (Verge et al., 1992).  
Following a nerve lesion, p75NTR expression decreases in the injured primary sensory 
neurons (Verge et al., 1992), however increased expression is observed in their uninjured 
primary sensory neighbours and in the surrounding SGCs (Obata et al., 2006).  
Comparatively, it was reported by Obata et al. (2006) that an increase in the 
immunoreactivity of p75NTR was observed in SGCs in the DRG, particularly around 
larger-sized neurons, following lumbar segment 5 (L5) nerve ligation injury.  However, 
this glial p75NTR upregulation was not observed in the adjacent non-injured lumbar 
segment 4 (L4) ganglia.  The application of a p75NTR inhibitory antibody to a pinched 
sciatic nerve animal model was sufficient to suppress neuronal expression of calcitonin 
gene-related peptide and p75NTR and significantly decrease mechanical allodynia (Fukui 
et al., 2010). 
In addition to the neurotrophins binding to either p75NTR or the Trk receptors, 
they can bind to a p75NTR/Trk complex.  Numerous reports describe either an allosteric 
or cooperative interaction between p75NTR and Trk (Bamji et al., 1998; Bibel et al., 
1999; Brennan et al., 1999; MacPhee and Barker, 1997; Maliartchouk and Saragovi, 
1997). Investigations regarding the p75NTR/TrkA complex binding its NGF ligand 
currently dominate the literature.  A structural study has revealed, based on the resulting 
crystal formation that the NGF dimer changes conformation after binding to p75NTR to 
form two NGF monomers with one p75NTR molecule between them (He and Garcia, 
2004) in contrast to the 2:2 stoichiometry of the NGF/TrkA complex without p75NTR.  
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This 2:1 NGF/p75NTR complex offers the possibility of creating a three molecule 
complex with TrkA.  Thus, the relative expression levels of NGF, p75NTR and TrkA 
would determine the likelihood of creating the various complexes and regulating 
downstream signaling. The ratio of p75NTR to TrkA appears to be the key in modulating 
binding affinity and the overall effects of NGF and NT-3 to either of these receptors 
(Brennan et al., 1999). The p75NTR to TrkA ratio also regulates 
internalization/mobilization rates of these proteins to the membrane (Makkerh et al., 
2005). 
 
1.5 An overview of the mechanism of action of anti-sense oligonucleotides  
Anti-sense technology was first used in 1977 by Paterson et al.  It consists of a 
single stranded exact mRNA sequence usually between 12 and 30 chemically stabilized 
oligonucleotides complimentary to a specific protein which blocks the translation of that 
protein’s mRNA within the cytoplasm (Pestka, 1992; See Figure 1.4).  Manufactured 
antisense oligonucleotides (AS) are optimized to bind the target mRNA as efficiently as 
possible while minimizing non-specific binding to other mRNA and proteins.  Uptake 
into the cells in vivo is associated with the transporter, p80, a transporter for negatively 
charged macromolecules (the oligonucleotide backbone of the AS is anionic), in addition 
to passive diffusion/endocytosis into the cells (Biognostik). Modern AS are much more 
efficient and nuclease-resistant in vivo, owing to chemical modifications including the 
addition of phosphorothioate stabilizing bonds (White et al., 2009). Significant specific 
protein production decrease in vivo is dependent on the route of administration, dosage 
and tissue uptake. 
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Figure 1.4 Mechanism of action of anti-sense technology.  Messenger RNA (mRNA) 
is transcribed from DNA in the nucleus.  It is then transported to the cytoplasm of the cell 
to be translated to a protein.  However, with the introduction of an anti-sense sequence 
(AS) (ie. one complementary to 15 bases of p75NTR mRNA that typically includes the 
initiation site), the p75NTR mRNA is prevented from undergoing translation, because the 
translational machinery cannot access the initiation site.  This technique requires an 
adequate and continuous infusion of the AS to effectively block a significant portion of 
the p75NTR mRNA from being translated by each cell.  Thus, it only significantly blocks 
p75NTR protein production for the duration of the lifetime of the AS. 
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In order to verify the uptake pattern of the infused substance, a fluorescein-tagged 
copy of the AS is infused and visualized within the cytoplasm of the target cells at 
different timelines.  Control oligonucleotides, also known as sense control (SC), consist 
of random oligonucleotide sequences that are nonhomologous to any known sequences 
(verified on the GenBank database) and are used to control for non-specific binding of 
the AS or the phosphorothioates to any proteins and substance-related side effects.  They 
are designed to contain a similar ratio of guanine-cytosine/uracil-adenine base pairs and 
be of a similar length. 
 This AS technology has previously been used by Barclay et al. (2002), Lai et al. 
(2002), Obata et al. (2006), and Wilson-Gerwing et al. (2009) to decrease target protein 
levels in the sensory system in vivo.  The infusion of p75NTR AS was demonstrated to 
effectively downregulate p75NTR protein levels in intact sensory neurons by Obata et al. 
(2006) compared to the infusion of the SC sequence or a vehicle infusion, however no 
significant difference was observed compared to non-infused controls.  Before utilizing 
this technology, it is therefore necessary to verify the effectiveness of the AS technology 
and to include controls for the intrathecal infusion technique (See Figure 1.5). 
 
1.6 Rationale  
Cellular signals underlying the development of neuropathic pain states in sensory 
ganglia following peripheral nerve injury are complex and include both positive signals 
generated as a result of the injury and negative signals due to altered availability to 
trophic support as a result of the injury.  While it is well accepted that injury-associated 
alterations in the phenotype and properties of the injured neuron contribute to this state, 
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Figure 1.5 Intrathecal infusion technique. Silastic tubing attached to an osmotic mini-
pump is inserted under the dura at the lumbar sacral junction and is slid rostrally to the 
level of the L5 dorsal root ganglia (DRG).  The AS is taken up presumably by the axons 
in the spinal and ventral roots to the neurons L4/L5/L6 DRG and the lumbar region of the 
spinal cord.  
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this is not the only axis impacted.  It is now becoming evident that injury induces changes 
in perineuronal glia and neighboring uninjured neuron phenotype that also drive this 
neuropathic state.   
Gaining a better understanding of the nature of the signals underlying these 
changes may help identify novel therapeutic targets to help attenuate pain states.  As 
neurotrophins have been shown to be major modulators of the phenotypic and 
physiological properties of this state by signaling via two very different classes of 
signaling molecules, I sought to determine the extent to which altered neuronal signaling 
via the common neurotrophin receptor p75NTR might impact the properties of intact 
sensory neurons such that they adopt an injury phenotype akin to that observed in the 
neuropathic pain state associated with nerve injury.  Intact neurons were examined so as 
to isolate the impact of attenuated p75NTR expression from the plethora of additional 
molecules altered as a result of the nerve injury. 
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2. Hypothesis and Specific Aims 
Supported by the data presented in the introduction, I hypothesize that reduced 
neuronal p75NTR expression leads to a reduction in neurotrophin signaling and 
altered neuron/perineuronal glial communication that results in induction of an injury 
phenotype associated with a neuropathic pain state.  
 
2.1 Specific Aims 
To test this hypothesis, I addressed the following objectives: 
(i) Examine whether intrathecal infusion of p75NTR AS is selectively taken up by 
neurons and not nonneuronal cells in the DRG as was observed for intrathecally delivered 
siRNA (Geremia et al., 2010);  
(ii) Examine the impact of reduced neuronal p75NTR on a phenotype associated with 
neuropathic pain states, namely NaV1.8, NaV1.9 and TrkA, bearing in mind that inducing 
a dramatic shift in neuronal phenotype markers in intact/uninjured neurons is difficult 
(Wilson-Gerwing et al., 2008); 
(iii) As reduced p75NTR expression is normally only observed in sensory neurons 
following peripheral nerve axotomy, I postulate that reduced neuronal p75NTR will 
result in altered communication between neurons and perineuronal/glial cells that mimics 
axotomy, thereby the shifting the expression of perineuronal/glial phenotypic markers, 
p75NTR, GFAP, Kir4.1, from that of an intact to a reactive state.  Thus, I will examine 
the impact of reducing neuronal p75NTR expression on perineuronal expression of 
markers associated with the reactive state. 
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3. Materials and methods  
 All animal procedures were approved by the University of Saskatchewan’s 
Committee on Animal Care and Supply under the guidelines of the Canadian Council on 
Animal Care (protocol 19920164).  A total of 22 male Wistar rats (Charles River 
Laboratories, St.Constant, QC) weighing 250–300g were used for the following set of 
experiments with 17 undergoing pump implantation and the other five as procedural 
controls. 
 
3.1 Pump implantation surgery  
Animals were anesthesized with a gas mixture of 1.5-2.5% isoflurane/97.5-98.5% 
oxygen and given an analgesic, buprenorphine (Temgesic, sc, 0.1-0.2 mg/kg), pre-
surgically and post-surgically. The rats underwent implantation of a mini-osmotic pump 
attached to sterile silastic tubing (Model 2001, Alza, Cupertino, CA), inserted at the 
lumbar sacral junction as per Verge et al. (1989) such that the tip of the silastic tubing lay 
intrathecally at the level of the L5 DRG. 
 
3.1.1. Osmotic pump preparation 
 Under sterile conditions, mini-osmotic pumps (Model 2001, Alza, Cupertino, CA) 
were assembled.  Each vial of oligonucleotide (OGN) purchased from either Genelink 
(NY, USA) or Biognostik (Gottingen, Germany) contained 100 µg. This was dissolved in 
225 µl of provided PBS dilution buffer, containing rat serum albumin (1 mg/µl), 
streptomycin (100 U/ml) and penicillin (100 U/ml). This resulted in enough solution to 
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inject into one pump.  The pumps were then attached to silastic tubing and placed in 0.1 
M PBS solution overnight to prime.  
 
3.1.2 Intrathecal delivery of p75 NTR anti-sense and sense control oligonucleotides 
Pumps continuously infused one of either four OGNs: fluorescein-tagged 
p75NTR OGN AS (5’ – CAGGGCGGCTAAAAG – 3’ (Genelink, NY, USA) (p75NTR-
F AS), fluorescein-tagged p75NTR OGN SC (5’ – ACTACTACACTAGACTAC – 3’) 
(Biognostik, Gottingen, Germany) (p75NTR-F SC), p75NTR OGN AS (5’ – 
CAGGGCGGCTAAAAG – 3’ (Biognostik, Gottingen, Germany) (p75NTR AS) or 
p75NTR OGN SC (5’ – ACTACTACACTAGACTAC – 3’) (Biognostik, Gottingen, 
Germany) (p75NTR SC). The fluorescein-tagged OGNs were infused in order to 
visualize their uptake pattern.  The pumps infused the OGNs at a rate of 1 µl/hr and a 
concentration of 0.5 nmol/ml. 
 
3.1.3 Animal perfusion and tissue preparation 
 The rats were killed at various time points according to the following criteria: 
p75NTR-F AS (n=2) 36 hours post-implantation surgery, p75NTR-F AS (n=2) 48 hours 
post-implantation surgery and p75NTR-F SC (n=3), p75NTR AS (n=5) and p75NTR SC 
(n=5) 7 days post-implantation surgery (control animals (n=5) were killed at the same 
time as the p75NTR AS and p75NTR SC groups).  The rats were deeply anesthetized and 
perfused transcardially with 0.1 M PBS, pH 7.4, followed by 4% paraformaldehyde in 0.1 
M PBS. The sciatic nerves, spinal cord, bilateral L4, L5 and L6 dorsal root ganglia were 
carefully removed and postfixed for 1-1.5h in 4% paraformaldehyde, then cryoprotected 
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in 10% sucrose followed by 20 % sucrose overnight at 4oC.  All ganglia were frozen with 
OCT compound (Tissue Tek; Miles Laboratories, Elkhart, IN) in a cryomold (Tissue Tek, 
Miles Laboratories).  The L4 and L5 ganglia were then cut transversally on a cryostat 
(Micron, Zeiss, Canada) into 8 µm sections and thaw mounted on Superfrost Plus slides 
(Fisher Scientific). 
 
3.2 Immunohistochemistry 
3.2.1 Visualization of fluorescein-tagged oligonucleotide 
 The slides were then washed three times in 0.1M PBS and coverslipped using 
Prolong Gold anti-fade reagent (Invitrogen – Molecular Probes #P36930, Carlsbad, CA).  
Images were taken on a Zeiss Axio Imager 1 system with Northern Eclipse® (Empix 
Imaging Inc.) software. 
 
3.2.2 Visualization of protein expression with antibodies 
  One week post-implantation surgery, the rats were deeply anesthesized and 
perfused transcardially with 0.1 M PBS, pH 7.4, followed by 4% paraformaldehyde in 0.1 
M PBS. The sciatic nerve, spinal cord, bilateral L4, L5 and L6 dorsal root ganglia were 
carefully removed and postfixed for 1-1.5h then cryoprotected in 10% sucrose followed 
by 20 % sucrose overnight at 4oC.  Experimental and control ganglia were embedded in a 
cryomold (Tissue Tek; Miles Laboratories, Elkhart, IN) with OCT compound (Tissue 
Tek, Miles Laboratories) as to ensure parallel processing.  The ganglia were then cut 
transversally on a cryostat (Micron, Zeiss, Canada) into 6 or 8 µm sections and thaw 
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mounted on Superfrost Plus slides (Fisher Scientific) for immunohistochemistry 
processing. 
Slides were blocked with 5% normal goat serum, 5% normal horse serum, 1.5% 
bovine serum albumin and 0.3% Triton X-100 overnight in 0.1 M PBS and subsequently 
treated with the following primary antibodies: mouse anti-p75NTR (Santa Cruz, CA, 
USA, 1:500), rabbit anti-NaV1.8 channel (Chemicon Intl, 1:200), rabbit anti-NaV1.9 
channel (Chemicon Intl, 1:100), rabbit anti-TrkA neurotrophin receptor (Cedarlane 
Laboratories, 1:1500), rabbit anti-GFAP (Dakopatts, 1:1000), mouse anti-connexin 43 
(Millipore Inc., 1:100) or rabbit anti-Kir4.1 channel (Alomone Inc., 1:500), in a solution 
comprised of 1% normal goat serum, 1% normal horse serum, 0.5% bovine serum 
albumin and 0.3% Triton X-100 overnight in 0.1 M PBS. After 0.1M PBS washes, the 
localization of the primary antibodies was visualized with goat anti-mouse Texas Red 
secondary antibody (Jackson Laboratories, USA, 1:200), goat anti-rabbit Alexa Fluor 488 
(Invitrogen, 1:250) or donkey anti-rabbit Cy3 F(ab’)2 fragment (Jackson Laboratories 
Inc., 1:600)  in a 0.1 M PBS solution at room temperature for one hour. Slides that were 
treated with anti-GFAP were subsequently double labeled with FITC-conjugated isolectin 
from griffonia simplicifolia (IB4) (Sigma, 1:20) in 0.1 M PBS at room temperature for 3 
hours.  The slides were then washed three times in 0.1M PBS and coverslipped using 
Prolong Gold anti-fade reagent with or without DAPI (Invitrogen – Molecular Probes 
#P36930, Carlsbad, CA).  Control sections were processed in the same manner while 
omitting the primary antibody.  All slides were stored at -20 degrees Celsius in light-
proof bags. 
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3.3 Quantification of immunohistochemical signal 
All slides were initially analyzed qualitatively and relative changes in 
immunohistochemistry labeling intensity between experimental groups were noted within 
each slide to omit discrepancies in background labeling intensity.  Slides were selected 
for experimental analysis such that they had similar numbers of neurons in the DRG 
sections representing each experimental group.  Analysis for p75NTR immunoreactive 
labeling intensity was performed on 9 DRG or 1208 neuronal profiles/1217-1568 SGC 
profiles  (non-infused: n=3 animals; p75NTR SC: n=3 animals; p75NTR AS: n=3).  
Images were taken under identical conditions for each DRG on individual slides on a 
Zeiss Axio Imager 1 microscope system with Northern Eclipse® (Empix Imaging Inc.) 
software using a 40X objective for quantitative neuronal analysis and a 20x objective for 
sciatic nerve sections selected for demonstrating qualitative changes in 
immunohistochemistry labeling intensity.  After photographing all sections on a slide, 
images of each DRG were taken with a 10X objective to create photomontages of each 
section to be analyzed which were then assembled using Adobe® Photoshop® CS3 
(Adobe Systems Inc., USA) to ensure that all neurons with a visible nucleus were only 
traced once.  For neuronal profiles, the circumference of the neuron was traced as well as 
the cytoplasm using tablet tracing software (Bamboo, Wacom Ltd, Japan) with inputs 
into Northern Eclipse® (Empix Imaging Inc.) which computed the diameter of each 
individual neuron and its respective average cytoplasmic immunohistochemical labeling 
intensity.  For SGC profiles, the circumference of the neuron was traced as well as the 
cytoplasm of its SGCs representing average labeling intensity around that respective 
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neuron.  Tablet tracing software (Bamboo, Wacom Ltd, Japan) was used with inputs into 
Northern Eclipse® (Empix Imaging Inc.) which computed the diameter of each 
individual neuron and the average immunohistochemical labeling intensity over the 
cytoplasm of the SGCs. Supplemental statistical and graphical manipulations were 
performed with Prizm 4.0 (Graph Pad Software, San Diego, CA) and Microsoft Excel 
(Microsoft Corp., USA). 
 
3.4 Statistical analysis 
Each data point for individual neurons analysed was normalized to the mean 
immunohistochemical labeling intensity from the non-infused control animal in its 
grouping using Microsoft Excel software (Microsoft Corp., USA).  A Kruskall-Wallis 
non-parametric ANOVA (Prizm 4.0, Graph Pad Software, San Diego, CA) was used to 
compare the cytoplasmic immunohistochemistry labeling intensity between treatment 
groups.  Statistical significance was accepted at p <0.05 level. Supplemental statistical 
and graphical manipulations were performed with Prizm 4.0 (Graph Pad Software, San 
Diego, CA) and Microsoft Excel (Microsoft Corp., USA). 
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4. Results 
 
4.1 Efficacy of intrathecal p75NTR anti-sense oligonucleotide treatment 
 Fluorescein-tagged p75NTR AS was infused intrathecally for 36 hours (n=2), 48 
hours (n=2) or 7 days (n=3) to determine its localization following uptake. The 
fluorescence was observed in and around the spinal cord at all time points.  The 
fluorescein signal was visualized in the DRG neurons as early as 36 hours, was more 
robust 48 hours after pump implantation (Figure 4.1.1), and was significantly reduced by 
7 days (Data not shown).  The fluorescein signal was not observed in the SGCs or in the 
extracellular space (Figure 4.1.1).   
 It should be noted that for all markers examined, similar qualitative trends were 
observed between experimental groups for all animals in each experimental group.  Three 
grouping of different experimental animals were then selected for detailed quantitative 
analysis based on the observation that similar numbers of neurons were present in each of 
the DRG sections on the slide. 
 In order to confirm the efficacy of the intrathecally infused p75NTR AS, sections 
processed for immunohistochemistry were analyzed to detect changes in the 
immunoreactive labeling intensity of p75NTR.  A 7 day intrathecal infusion of p75NTR 
AS resulted in significantly decreased neuronal cytoplasmic immunoreactive labeling 
intensity of p75NTR over all size ranges of neurons compared to non-infused and 
p75NTR SC controls in the DRG (Figures 4.1.2, 4.1.3 and 4.1.4).  Each neuronal data 
point was normalized to the mean immunohistochemical labeling intensity from the non-
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infused control animal in its grouping.  It was thus observed that the percentage of data 
points above the mean	  immunohistochemical labeling intensity of the non-infused control  
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Figure 4.1.1 Intrathecally infused fluorescein-tagged p75NTR AS localizes to 
sensory neurons in the dorsal root ganglion and not surrounding satellite glial cells.  
Fluorescence photomicrographs of L5 DRG sections processed for 
immunohistochemistry depict the localization of fluorescein-tagged p75NTR AS OGN in 
small, medium and large neurons however not in the SGCs in L5 DRG from uninjured 
intact rats.  Scale bar = 50 µm 
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Figure 4.1.2 Cytoplasmic neuronal p75NTR immunoreactive labeling intensity is 
decreased with p75NTR AS.  Fluorescence photomicrographs of L5 DRG sections 
processed for immunohistochemistry depict p75NTR protein expression in the cytoplasm 
of neurons in L5 DRG from uninjured intact rats in control non-infused (A), p75NTR SC 
infused (B) and p75NTR AS infused (C).  Note: Intrathecal infusion of p75NTR AS 
OGN (C) results in decreased immunoreactive labeling intensity of p75NTR protein in 
neurons compared to control non-infused (A) and p75NTR SC OGN infused (B) 
treatment groups.  This decreased immunoreactive labeling intensity of p75NTR is most 
evident in the heavily labeled population (Arrows).  Infusion of p75NTR AS does 
however result in increased immunoreactive labeling intensity of p75NTR protein in 
SGCs (discussed in Results Section 5.4.2).  Scale bar = 50 µm 
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Figure 4.1.3 Cytoplasmic neuronal p75NTR immunoreactive labeling intensity is 
decreased with p75NTR AS.  Scatter plots depict quantification of immunoreactive 
labeling intensity of p75NTR protein expression in the cytoplasm of neurons in L5 DRG 
from uninjured intact rats treated as indicated and normalized to the mean labeling 
intensity in neurons from the non-infused control animal in its grouping.  Note: 
Intrathecal infusion of p75NTR AS OGN (n=3) results in a decrease in expression of 
p75NTR in neurons compared to non-infused (n=3) and p75NTR SC OGN infused (n=3) 
treatment groups.  N= A total of 375 to 445 neurons analyzed per treatment group. 
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Figure 4.1.4 Mean cytoplasmic neuronal p75NTR immunoreactive labeling intensity 
is significantly decreased with p75NTR AS.  Graph depicts quantification of relative 
changes in mean immunoreactive labeling intensity of p75NTR protein expression in the 
cytoplasm of neurons in L5 DRG from uninjured intact rats treated as indicated and 
normalized to the mean labeling intensity in neurons from the non-infused control animal 
in its grouping.  Note: Intrathecal infusion of p75NTR AS OGN (n=3) results in a 
significant decrease in expression of p75NTR in neurons compared to non-infused (n=3) 
and p75NTR SC OGN infused (n=3) treatment groups.  Asterisks indicate significant 
differences between experimental groups (Kruskal-Wallis test with Dunn’s Multiple 
Comparison test; * p<0.01, *** p<0.0001).  Bars represent the standard error of the mean 
(s.e.m.).  N= A total of 375 to 445 neurons analyzed per treatment group. 
*****
*	  
***	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group (>1.00) from the p75NTR AS infused group decreased to 20.36% (0.013133 
s.e.m.) from 39.78% (0.017141 s.e.m.) for the non-infused control group and 36.80% 
(0.016958 s.e.m.) for the p75NTR SC infused group (Figure 4.1.3).  The average mean 
immunoreactive labeling intensity of p75NTR was significantly lower for the p75NTR 
AS treated group compared to the p75NTR SC treated and the non-infused groups 
(0.8458 +/- 0.00940 (s.e.m.) compared to 0.9812 +/- 0.01214 (s.e.m.) and 1.0000 +/- 
0.01154 (s.e.m.) respectively) (Kruskal-Wallis test with Dunn’s Multiple Comparison 
test, p<0.0001) (Figure 4.1.4).  It was noted however that the p75NTR AS infusion 
produced a marked increase in the immunoreactive labeling intensity of p75NTR in the 
SGCs (See Section 4.1.2). 
 
4.2 Impact of reduced neuronal p75NTR expression on phenotype associated with 
neuropathic pain states in intact sensory neurons 
 
 
4.2.1 Neuronal Na+ channel expression 
 
Immunohistochemistry revealed that in the intact state, independent of infusion 
treatment, NaV1.8 protein was observed most prominently in the smaller DRG neurons, 
with some medium to large sized neurons also expressing low to moderate levels of 
NaV1.8 protein (Figure 4.2.1.1).  A 7 day intrathecal infusion of either p75NTR AS or 
p75NTR SC was ineffective at altering levels of neuronal NaV1.8 protein compared to the 
non-infused treatment group.  Each data point was normalized to the mean 
immunohistochemical labeling intensity from the non-infused control animal in its 
grouping.  It was thus observed that the percentage of data points above the mean 
immunohistochemical labeling intensity of the non-infused control group (>1.00) from  
	   45	  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.2.1.1 Neuronal NaV1.8 immunoreactive labeling intensity in DRG does not 
discernably change with intrathecal infusion of either p75NTR AS OGN or p75NTR 
SC OGN compared to non-infused controls. Fluorescence photomicrographs of L5 
DRG sections processed for immunohistochemistry depict NaV1.8 protein expression in 
the cytoplasm of neurons in L5 DRG from uninjured intact rats in control non-infused 
(A), p75NTR SC infused (B) and p75NTR AS infused (C). Note: Intrathecal infusion of 
p75NTR AS OGN (C) or p75NTR SC OGN (B) does not result in discernable change in 
NaV1.8 protein expression compared to non-infused (A) controls in small-medium 
neurons.  However, there appears to be reduced expression in the very large neurons 
(Arrows).  Scale bar: 50 µm 
A B 
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the p75NTR AS infused group did not vary markedly compared to p75NTR SC infused 
or the non-infused control group (38.88% (0.02332 s.e.m.) compared to 40.19% (0.02694 
s.e.m.) and 45.57% (0.02931 s.e.m.) respectively) (Figure 4.2.1.2).  This was also shown 
in terms of the mean immunoreactive labeling intensity of NaV1.8 with no significant 
differences between non-infused (1.0000 +/- 0.02931 (s.e.m.)), p75NTR SC infused 
(0.9414 +/- 0.02694 (s.e.m.)) or the p75NTR AS infused (0.9005 +/- 0.02332 (s.e.m.)) 
treatment groups (Figure 4.2.1.3).  We observed however a small decrease in the 
percentage of data points above 1.00 in the larger sized neurons (diameter >50 mm) of 
the p75NTR AS treated group (0.362% (0.02332 s.e.m.) compared to the p75NTR SC 
treated (3.962% (0.02694 s.e.m.) and the non-infused control group (6.048% (0.0293 
s.e.m.)) (Figure 4.2.1.2).  This was also shown in terms of the mean immunoreactive 
labeling intensity of NaV1.8 being slightly decreased in larger sized neurons (diameter 
>50 mm) following p75NTR AS infusion (0.3737 +/- 0.02700 (s.e.m.) compared to no 
infusion (0.6269 +/- 0.05247 (s.e.m.))  (Kruskal-Wallis test with Dunn’s Multiple 
Comparison test, p<0.01) (Figure 4.2.1.3).  
The levels of observed immunoreactive labeling intensity of NaV1.8 in sections of 
DRG were consistent with those observed in their corresponding intact sciatic nerve 
(Figure 4.2.1.4). This suggests that lack of variability in the observable NaV1.8 protein 
levels between experimental groups was not due to shuttling of the protein to the axons 
from the cell bodies.  
 Immunohistochemistry revealed that in the intact state, independent of infusion 
treatment, NaV1.9 protein was observed most prominently in the smaller DRG neurons, 
with some medium to large sized neurons also expressing low to moderate levels of  
	   47	  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.2.1.2 Neuronal NaV1.8 immunoreactive labeling intensity in DRG does not 
vary with intrathecal infusion of either p75NTR AS OGN or p75NTR SC OGN 
compared to non-infused controls.  Scatter plots depict quantification of 
immunoreactive labeling intensity of NaV1.8 protein expression in neurons in L5 DRG 
from uninjured intact rats treated as indicated and normalized to the mean signal labeling 
intensity in neurons from the non-infused control animal in its grouping.  Note: 
Intrathecal infusion of p75NTR AS OGN (n=3) or p75NTR SC OGN (n=3) did not result 
in any noted changes in the expression levels of NaV1.8 protein in small-medium neurons 
compared to the non-infused (n=3) treatment group.  However, there is a decrease in 
expression in the larger (>50 µm) neurons.  N= A total of 463 to 552 neurons analyzed 
per treatment group. 
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Figure 4.2.1.3 Mean neuronal NaV1.8 immunoreactive labeling intensity in DRG 
does not vary greatly with intrathecal infusion of either p75NTR AS OGN or 
p75NTR SC OGN compared to non-infused controls.  Graph depicts quantification of 
immunoreactive labeling intensity of NaV1.8 protein expression in neurons in L5 DRG 
from uninjured intact rats treated as indicated and normalized to the mean signal labeling 
intensity in neurons from the non-infused control animal in its grouping.  Note: 
Intrathecal infusion of p75NTR AS OGN (n=3) or p75NTR SC OGN (n=3) did not result 
in any significant changes in the expression levels of NaV1.8 protein in small-medium 
neurons compared to the non-infused (n=3) treatment group.  However, there was a slight 
decrease in NaV1.8 protein expression in large neurons in the p75NTR AS OGN treated 
group compared to large neurons in the non-infused treatment group.  Kruskal-Wallis test 
with Dunn’s Multiple Comparison test; * p<0.01).  Bars represent the standard error of 
the mean (s.e.m.).  N= A total of 463 to 552 neurons analyzed per treatment group. 
 
*	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Figure 4.2.1.4 Neuronal NaV1.8 immunoreactive labeling intensity in sciatic nerves 
does not discernably change with intrathecal infusion of either p75NTR AS OGN or 
p75NTR SC OGN compared to non-infused controls. Fluorescence photomicrographs 
of sciatic nerve sections processed for immunohistochemistry depict NaV1.8 protein 
expression in axons from uninjured intact rats in control non-infused (A), p75NTR SC 
infused (B) and p75NTR AS infused (C).  Note: Intrathecal infusion of p75NTR AS 
OGN (C) or p75NTR SC OGN (B) does not result in discernable changes in NaV1.8 
protein expression compared to non-infused (A) controls.  Scale bar = 100 µm 
C 
B A 
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NaV1.9 protein (Figure 4.2.1.5).  A 7 day intrathecal infusion of either p75NTR AS or 
p75NTR SC was ineffective at altering levels of neuronal NaV1.9 protein compared to the 
non-infused treatment group.  Each data point was normalized to the mean 
immunohistochemical labeling intensity from the non-infused control animal in its 
grouping.  It was thus observed that the percentage of data points above the mean 
immunohistochemical labeling intensity of the non-infused control group (>1.00) from 
the p75NTR AS infused group did not vary markedly compared to p75NTR SC infused 
or the non-infused control group (40.85% (0.01527 s.e.m.) compared to 37.80%, 0.9330 
(0.02002 s.e.m.) and 44.49% (0.01928 s.e.m.) respectively) (Figures 4.2.1.6).  This was 
also shown in terms of the mean immunoreactive labeling intensity of NaV1.9 with no 
significant differences between non-infused (1.0000 +/- 0.01928 (s.e.m.)), p75NTR SC 
infused (0.9330 +/- 0.02002 (s.e.m.)) or the p75NTR AS infused (0.9446 +/- 0.01527 
(s.e.m.)) treatment groups (Figure 4.2.1.7).  
The levels of expression observed in sections of DRG were consistent with those 
observed in their corresponding intact sciatic nerve (Figure 4.2.1.8).  This suggests that 
lack of variability in the observable NaV1.9 protein levels between experimental groups 
was not due to shuttling of the protein to the axons from the cell bodies. 
 
4.2.2 Neuronal TrkA expression 
Immunohistochemistry revealed that in the intact state, independent of infusion 
treatment, TrkA protein was observed most prominently in the smaller DRG neurons, 
with some medium to large sized neurons also expressing low to moderate levels of TrkA  
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Figure 4.2.1.5 Neuronal NaV1.9 immunoreactive labeling intensity in DRG does not 
discernably change with intrathecal infusion of either p75NTR AS OGN or p75NTR 
SC OGN compared to non-infused controls. Fluorescence photomicrographs of L5 
DRG sections processed for immunohistochemistry depict NaV1.9 protein expression in 
the cytoplasm of neurons in L5 DRG from uninjured intact rats in control non-infused 
(A), p75NTR SC infused (B) and p75NTR AS infused (C).  Note: Intrathecal infusion of 
p75NTR AS OGN (C) or p75NTR SC OGN (B) does not result in any discernable 
change in NaV1.9 protein expression compared to non-infused (A) controls.  Scale bar: 50 
µm 
A B 
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Figure 4.2.1.6 Neuronal NaV1.9 immunoreactive labeling intensity in DRG does not 
vary with intrathecal infusion of either p75NTR AS OGN or p75NTR SC OGN 
compared to non-infused controls.  Scatter plots depict quantification of 
immunoreactive labeling intensity of NaV1.9 protein expression in neurons in L5 DRG 
from uninjured intact rats treated as indicated and normalized to the mean signal labeling 
intensity in neurons from the non-infused control animal in its grouping.  Note: 
Intrathecal infusion of p75NTR AS OGN (n=3) or p75NTR SC OGN (n=3) did not result 
in any noted changes in the expression levels of NaV1.9 protein in neurons compared to 
the non-infused (n=3) treatment group.  N= A total of 410 to 590 neurons analyzed per 
treatment group. 
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Figure 4.2.1.7 Mean neuronal NaV1.9 immunoreactive labeling intensity in DRG 
does not vary significantly with intrathecal infusion of either p75NTR AS OGN or 
p75NTR SC OGN compared to non-infused controls.  Graph depicts quantification of 
relative changes in mean immunoreactive labeling intensity of NaV1.9 protein expression 
in neurons in L5 DRG from uninjured intact rats treated as indicated and normalized to 
the mean signal labeling intensity in neurons from the non-infused control animal in its 
grouping.  Note: Intrathecal infusion of p75NTR AS OGN (n=3) or p75NTR SC OGN 
(n=3) did not result in any significant differences in the expression levels of NaV1.9 
protein in neurons compared to the non-infused (n=3) treatment group.  Bars represent 
the standard error of the mean (s.e.m.).  N= A total of 410 to 590 neurons analyzed per 
treatment group. 
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Figure 4.2.1.8 Neuronal NaV1.9 immunoreactive labeling intensity in sciatic nerves 
does not discernably change with intrathecal infusion of either p75NTR AS OGN or 
p75NTR SC OGN compared to non-infused controls. Fluorescence photomicrographs 
of sciatic nerve sections processed for immunohistochemistry depict NaV1.9 protein 
expression in the axons from uninjured intact rats in control non-infused (A), p75NTR 
SC infused (B) and p75NTR AS infused (C).  Note: Intrathecal infusion of p75NTR AS 
OGN (C) or p75NTR SC OGN (B) does not result in any discernable change in NaV1.9 
protein expression compared to non-infused (A) controls.  Scale bar: 100 µm 
A B 
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protein (Figure 4.2.2.1).  A 7 day intrathecal infusion of either p75NTR AS or p75NTR 
SC was ineffective at altering levels of neuronal TrkA protein compared to the non-
infused treatment group.  Each data point was normalized to the mean 
immunohistochemical labeling intensity from the non-infused control animal in its 
grouping.  It was thus observed that the percentage of data points above the mean 
immunohistochemical labeling intensity of the non-infused control group (>1.00) from 
the p75NTR AS infused group did not vary markedly compared to p75NTR SC infused 
or the non-infused control group (39.94% (0.01071 s.e.m.) compared to 35.33% (0.01474 
s.e.m.) and 39.78% (0.01170 s.e.m.) respectively) (Figure 4.2.2.2).  This was also shown 
in terms of the mean immunoreactive labeling intensity of TrkA with no significant 
differences between non-infused (1.0000 +/- 0.01170 (s.e.m.)), p75NTR SC infused 
(1.0144 +/- 0.01474 (s.e.m.) or the p75NTR AS infused (1.0078 +/- 0.01071 (s.e.m.) 
treatment groups (Figure 4.2.2.3).  
The levels of expression observed in sections of DRG were consistent with those 
observed in their corresponding intact sciatic nerve (Figure 4.2.2.4).  This suggests that 
lack of variability in the observable TrkA protein levels between experimental groups 
was not due to shuttling of the protein to the axons from the cell bodies.  It is of note that 
some TrkA immunoreactivity was observed in the perineuronal area in all treatment 
groups with a slight increase seen with p75NTR AS treatment. 
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Figure 4.2.2.1 Neuronal TrkA immunoreactive labeling intensity in DRG does not 
discernably change with intrathecal infusion of either p75NTR AS OGN or p75NTR 
SC OGN compared to non-infused controls. Fluorescence photomicrographs of L5 
DRG sections processed for immunohistochemistry depict TrkA protein expression in the 
cytoplasm of neurons in L5 DRG from uninjured intact rats in control non-infused (A), 
p75NTR SC infused (B) and p75NTR AS infused (C).  Note: Intrathecal infusion of 
p75NTR AS OGN (C) or p75NTR SC OSN (B) does not result in any discernable change 
in TrkA protein expression compared to non-infused (A) controls.  Scale bar: 50 µm 
A B 
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Figure 4.2.2.2 Neuronal TrkA immunoreactive labeling intensity in DRG does not 
vary with intrathecal infusion of either p75NTR AS OGN or p75NTR SC OGN 
compared to non-infused controls.  Scatter plots depict quantification of 
immunoreactive labeling intensity of TrkA protein expression in neurons in L5 DRG 
from uninjured intact rats treated as indicated and normalized to the mean signal labeling 
intensity in neurons from the non-infused control animal in its grouping.  Note: 
Intrathecal infusion of p75NTR AS OGN (n=3) or p75NTR SC OGN (n=3) did not result 
in any noted changes in the expression levels of TrkA protein in neurons compared to the 
non-infused (n=3) treatment group.  N= A total of 433 to 445 neurons analyzed per 
treatment group. 
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Figure 4.2.2.3 Mean neuronal TrkA immunoreactive labeling intensity in DRG does 
not vary significantly with intrathecal infusion of either p75NTR AS OGN or 
p75NTR SC OGN compared to non-infused controls.  Graph depicts quantification of 
relative changes in mean fluorescence labeling intensity of TrkA protein expression in 
neurons in L5 DRG from uninjured intact rats treated as indicated and normalized to the 
mean signal labeling intensity in neurons from the non-infused control animal in its 
grouping.  Note: Intrathecal infusion of p75NTR AS OGN (n=3) or p75NTR SC OGN 
(n=3) did not result in any significant differences in the expression levels of TrkA protein 
in neurons compared to the non-infused (n=3) treatment group.  Bars represent the 
standard error of the mean (s.e.m.).  N= A total of 433 to 445 neurons analyzed per 
treatment group. 
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Figure 4.2.2.4 Neuronal TrkA immunoreactive labeling intensity in sciatic nerves 
does not discernably change with intrathecal infusion of either p75NTR AS OGN or 
p75NTR SC OGN compared to non-infused controls.  Fluorescence photomicrographs 
of right sciatic nerve sections processed for immunohistochemistry depict TrkA protein 
expression in axons from uninjured intact rats in control non-infused (A), p75NTR SC 
infused (B) and p75NTR AS infused (C).  Note: Intrathecal infusion of p75NTR AS 
OGN (C) or p75NTR SC OGN (B) does not result in any discernable change in TrkA 
protein expression compared to non-infused (A) controls.  Scale bar: 100 µm 
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4.3 Impact of reduced neuronal p75NTR expression on satellite glial cell phenotype 
associated with neuropathic pain states 
 
4.3.1 Satellite glial cell GFAP expression 
 
Analysis of DRG sections processed for immunohistochemistry to detect glial 
levels of immunoreactive labeling intensity of GFAP protein revealed that 7 day 
intrathecal infusion of p75NTR AS resulted in increased the immunoreactive labeling 
intensity compared to non-infused and p75NTR SC controls (Figure 4.3.1.1).  This 
increased expression of glial GFAP protein was also observed in sciatic nerve sections 
(Figure 4.3.1.2).  Each data point was normalized to the mean immunohistochemical 
labeling intensity from the non-infused IB4+ control animal in its grouping.  Neurons that 
did not label with isolectin from griffonia simplicifolia (IB4) had a higher 
immunoreactive labeling intensity (<2) of GFAP protein in their surrounding SGCs 
following p75NTR AS treatment (54.43% +/- 0.05400 (s.e.m.)) compared to p75NTR SC 
infusion (6.46% +/- 0.03390 (s.e.m.)) or non-infused controls (10.15%+/- 0.34223 
(s.e.m.)) (Figure 4.3.1.3). Neurons that were negative for IB4 had a significantly higher 
mean immunoreactive labeling intensity of GFAP protein in their surrounding SGCs 
compared to neurons that did label for IB4 across all treatment groups (from 1.0000 +/- 
0.02938 (s.e.m.) to 1.2681 +/- 0.03422 (s.e.m.) (non-infused), 0.8951 +/- 0.03098 (s.e.m.) 
to 1.1889 +/- 0.03390 (s.e.m.) (SC), 1.3745 +/- 0.03694 (s.e.m.) to 2.3273 +/- 0.05400 
(s.e.m.) AS) (Kruskal-Wallis test with Dunn’s Multiple Comparison test, p<0.0001) 
(Figure 4.3.1.4).  The mean immunoreactive labeling intensity of GFAP in SGCs 
surrounding IB4-positive neurons increased significantly in the p75NTR AS infused 
(1.3745 +/- 0.03694 (s.e.m.)) treatment group compared to the non-infused (1.0000 +/-  
 
	   61	  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.3.1.1 Satellite glial cell GFAP immunoreactive labeling intensity is 
dramatically increased in response to p75NTR AS treatment and is most evident in 
satellite glial cells surrounding the subpopulation of IB4 non-labeled neurons.  Top:  
Fluorescence photomicrographs of L5 DRG sections processed for 
immunohistochemistry depict GFAP protein expression in the cytoplasm of SGCs in L5 
DRG from uninjured intact rats in control non-infused (A), p75NTR SC infused (B) and 
p75NTR AS infused (C).  Note: Intrathecal infusion of p75NTR AS OGN (C) results in 
increased expression of GFAP in SGCs compared to control non-infused (A) and 
p75NTR SC OGN infused (B) treatment groups.  Bottom: Fluorescence 
photomicrographs of DRG sections that are processed for GFAP immunohistochemistry 
and double-labeled with FITC-conjugated lectin from Griffonia simplicifolia (IB4) in 
order to discern alterations in GFAP expression in SGCs (D) surrounding IB4-negative 
(large arrows) and IB4-positive neurons (small arrows) (E).  Note: Expression of GFAP 
protein is higher in SGCs surrounding IB4-negative neurons compared to SGCs 
surrounding IB4-positive neurons.  Scale bars = 50 µm 
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Figure 4.3.1.2 Glial/Schwann cells GFAP immunoreactive labeling intensity is 
dramatically increased in response to p75NTR AS treatment in sciatic nerves.   
Fluorescence photomicrographs of sciatic nerve sections processed for 
immunohistochemistry depict GFAP protein expression in axons from uninjured intact 
rats in control non-infused (A), p75NTR SC infused (B) and p75NTR AS infused (C).  
Note: Intrathecal infusion of p75NTR AS OGN (C) results in increased expression of 
GFAP in glial/Schwann cells compared to control non-infused (A) and p75NTR SC OGN 
infused (B) treatment groups.  Scale bar: 50 µm 
B 
C 
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Figure 4.3.1.3 Satellite glial cell GFAP immunoreactive labeling intensity is 
increased with p75NTR AS treatment surrounding both IB4 positively labeled and 
IB4 non-labeled neurons.  Scatter plots depict quantification of relative changes in 
normalized immunoreactive labeling intensity of GFAP protein expression in SGCs in L5 
DRG from uninjured intact rats treated as indicated and normalized to the mean signal 
labeling intensity in SGCs from the non-infused IB4+ control animal in its grouping.  
Note: Intrathecal infusion of p75NTR AS OGN (n=3) results in a significant increase in 
expression of GFAP in SGCs compared to non-infused (n=3) and p75NTR SC OGN 
infused (n=3) treatment groups.  Within this population, SGCs surrounding IB4 negative 
neurons had a significantly higher expression of GFAP compared to IB4 positive 
neurons.  N= A total of 515 to 538 SGCs analyzed per treatment group with a total of 3 
animals in each group. 
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Figure 4.3.1.4 Mean satellite glial cell GFAP immunoreactive labeling intensity is 
significantly increased with p75NTR AS treatment surrounding both IB4 positively 
labeled and IB4 non-labeled neurons.  Graph depicts quantification of relative changes 
in normalized mean immunoreactive labeling intensity of GFAP protein expression in 
SGCs in L5 DRG from uninjured intact rats treated as indicated and normalized to the 
mean signal labeling intensity in SGCs from the non-infused IB4+ control animal in its 
grouping.  Note: Intrathecal infusion of p75NTR AS OGN (n=3) results in a significant 
increase in expression of GFAP in SGCs compared to non-infused (n=3) and p75NTR SC 
OGN infused (n=3) treatment groups.  Within this population, SGCs surrounding IB4 
negative neurons had a significantly higher expression of GFAP compared to IB4 
positive neurons.  Asterisks indicate significant differences between experimental groups 
(Kruskal-Wallis test with Dunn’s Multiple Comparison test; *** p<0.0001).  Bars 
represent the standard error of the mean (s.e.m.).  N= A total of 515 to 538 SGCs 
analyzed per treatment group with a total of 3 animals in each group. 
***	  
***	  
***	   ***	  
***	  
***	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0.02938 (s.e.m.)) and p75NTR SC infused (0.8951 +/- 0.03098 (s.e.m.)) treatment 
groups.  The mean immunoreactive labeling intensity of GFAP in SGCs surrounding 
IB4-negative neurons increased significantly in the p75NTR AS infused (2.3273 +/- 
0.05400 (s.e.m.)) treatment group compared to the non-infused (1.2681 +/- 0.03422 
(s.e.m.)) and p75NTR SC (1.1889 +/- 0.03390 (s.e.m.)) infused treatment groups.  
 The levels of observed immunoreactive labeling intensity of GFAP in sections of 
sciatic nerve were consistent with those observed in their corresponding intact DRG 
(Figure 4.3.1.2). 
 
4.3.2 Satellite glial cell p75NTR expression 
 
Analysis of sections processed for immunohistochemistry to detect glial 
expression of p75NTR protein revealed that a 7 day intrathecal infusion of p75NTR AS 
increased the immunoreactive labeling intensity compared to non-infused and p75NTR 
SC controls (Figure 4.3.2.1).  Each data point was normalized to the mean 
immunohistochemical labeling intensity from the non-infused control animal in its 
grouping.  It was thus observed that the percentage of data points above the mean 
immunohistochemical labeling intensity of the non-infused control group (>1.00) from 
the p75NTR AS infused group increased to 93.51% (0.02038 s.e.m.) from 45.67% 
(0.00898 s.e.m.) for the non-infused control group and 48.89% (0.01523 s.e.m.) for the 
p75NTR SC infused group (Figure 4.3.2.2).  The average mean immunoreactive labeling 
intensity of p75NTR was significantly higher for the p75NTR AS treated group 
compared to the p75NTR SC treated and the non-infused groups (1.4935 +/- 0.02038 
(s.e.m.) compared to 1.0168 +/- 0.01523 (s.e.m.) and 1.0000 +/- 0.00898 (s.e.m.)  
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Figure 4.3.2.1 Satellite glial cell p75NTR immunoreactive labeling intensity is 
dramatically increased with p75NTR AS.  Fluorescence photomicrographs of L% 
DRG  sections processed for immunohistochemistry depict p75NTR protein expression in 
the cytoplasm of SGCs from uninjured intact rats in control non-infused (A), p75NTR SC 
infused (B) and p75NTR AS infused (C). Note: Intrathecal infusion of p75NTR AS OGN 
(C) results in increased expression of p75NTR in SGCs compared to control non-infused 
(A) and p75NTR SC OGN infused (B) treatment groups.  Scale bar = 50 µm 
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Figure 4.3.2.2 Satellite glial cell p75NTR immunoreactive labeling intensity is 
increased with p75NTR AS treatment.  Scatter plots depict quantification of relative 
changes in normalized immunoreactive labeling intensity of p75NTR protein expression 
in SGCs in L5 DRG from uninjured intact rats treated as indicated and normalized to the 
mean signal labeling intensity in SGCs from the non-infused control animal in its 
grouping.  Note: Intrathecal infusion of p75NTR AS OGN (n=3) results in an increase in 
expression of p75NTR in SGCs compared to non-infused (n=3) and p75NTR SC OGN 
infused (n=3) treatment groups.  N= A total of 385 to 427 SGCs analyzed per treatment 
group with a total of 3 animals in each group. 
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respectively) (Kruskal-Wallis test with Dunn’s Multiple Comparison test, p<0.0001) 
(Figure 4.3.2.3). 
 
4.3.3 Satellite glial cell Kir4.1 expression 
 
Analysis of sections processed for immunohistochemistry to detect glial 
expression of Kir4.1 protein revealed that 7 day intrathecal infusion of p75NTR AS 
decreased the immunoreactive labeling intensity compared to non-infused and p75NTR 
SC controls (Figure 4.3.3.1).  Each data point was normalized to the mean 
immunohistochemical labeling intensity from the non-infused control animal in its 
grouping.  The percentage of neurons with surrounding SGCs expressing detectable 
Kir4.1 immunoreactive signal (ie. data points above the mean immunohistochemical 
labeling intensity of the non-infused control group (>1.00)) decreased from 44.14% 
(0.01138 s.e.m.) for the non-infused group to 22.83% (0.00884 s.e.m.) for the p75NTR 
SC infused group and further to 0.59% (0.00641 s.e.m.) for the AS infused control group 
(Figure 4.3.3.2).  Unlike all other markers examined, Kir4.1 was the only marker where a 
significant change was observed in response to sense control infusion.  Intrathecal 
infusion of the sense control, (p75NTR SC), was sufficient to significantly decrease the 
mean Kir4.1 immunoreactive labeling intensity compared to non-infused controls (from 
1.0005 +/- 0.01138 (s.e.m.) to 0.8652 +/- 0.00884 (s.e.m.)), however p75NTR AS 
infusion resulted in a significantly lower mean immunoreactive labeling intensity and 
greater overeall reducation in signal intensity than the p75NTR SC infusion (0.6009 +/- 
0.00641 (s.e.m.) compared to 0.8652 +/- 0.00884 (s.e.m.) respectively (Kruskal-Wallis 
test with Dunn’s Multiple Comparison test, p<0.0001) (Figure 4.3.3.3). 
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Figure 4.3.2.3 Mean satellite glial cell p75NTR immunoreactive labeling intensity is 
significantly increased with p75NTR AS treatment.  Graph depicts quantification of 
relative changes in mean immunoreactive labeling intensity of p75NTR protein 
expression in SGCs in uninjured intact L5 DRG from rats treated as indicated and 
normalized to the mean labeling intensity in SGCs from the non-infused control animal in 
its grouping. Note: Intrathecal infusion of p75NTR AS OGN (n=3) results in a significant 
increase in expression of p75NTR in SGCs compared to non-infused (n=3) and p75NTR 
SC OGN infused (n=3) treatment groups.  Asterisks indicate significant differences 
between experimental groups (Kruskal-Wallis test with Dunn’s Multiple Comparison 
test; *** p<0.0001).  Bars represent the standard error of the mean (s.e.m.).  N= A total of 
385 to 427 SGCs analyzed per treatment group. 
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Figure 4.3.3.1 Satellite glial cell Kir4.1 immunoreactive labeling intensity is 
decreased with p75NTR AS and p75NTR SC treatment. Fluorescence 
photomicrographs of L5 DRG sections processed for immunohistochemistry depict Kir4.1 
protein expression in the cytoplasm of SGCs from uninjured intact rats in control non-
infused (A), p75NTR SC infused (B) and p75NTR AS infused (C).  Note: Intrathecal 
infusion of p75NTR AS OGN (C) results in decreased expression of Kir4.1 in both 
neuronal and SGCs compared to control non-infused (A) and p75NTR SC OGN infused 
(B) treatment groups.  Intrathecal infusion of p75NTR SC OGN (B) also resulted in a 
modest decrease in Kir4.1 compared to non-infused (A) albeit the mean labeling intensity 
was significantly higher than the p75NTR AS OGN (C) treated.  Scale bar = 50 µm 
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Figure 4.3.3.2 Satellite glial cell Kir4.1 immunoreactive labeling intensity is 
decreased with p75NTR AS and p75NTR SC treatment.  Scatter plots depict 
quantification of relative changes in mean immunoreactive labeling intensity of Kir4.1 
protein expression in SGCs in L5 DRG from uninjured intact rats treated as indicated and 
normalized to the mean labeling intensity in SGCs from the non-infused control animal in 
its grouping.  Note: Intrathecal infusion of p75NTR AS OGN (n=3) results in a decrease 
in expression of Kir4.1 in SGCs compared to non-infused (n=3) and p75NTR SC OGN 
infused (n=3) treatment groups. Intrathecal infusion of p75NTR SC OGN also resulted in 
a decrease in Kir4.1 compared to non-infused albeit the immunoreactive labeling intensity 
was higher than the p75NTR AS OGN treated.  N= A total of 460 to 513 SGCs analyzed 
per treatment group. 
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Figure 4.3.3.3 Mean satellite glial cell Kir4.1 immunoreactive labeling intensity is 
significantly decreased with p75NTR AS and p75NTR SC treatment.  Graph depicts 
quantification of relative changes in mean immunoreactive labeling intensity of Kir4.1 
protein expression in SGCs in L5 DRG from uninjured intact rats treated as indicated and 
normalized to the mean labeling intensity in SGCs from the non-infused control animal in 
its grouping.  Note: Intrathecal infusion of p75NTR AS OGN (n=3) results in a 
significant decrease in expression of Kir4.1 in SGCs compared to non-infused (n=3) and 
p75NTR SC OGN infused (n=3) treatment groups.  Intrathecal infusion of p75NTR SC 
OGN also resulted in a significant decrease in Kir4.1 compared to non-infused albeit the 
mean immunoreactive labeling intensity was significantly higher than the p75NTR AS 
OGN treated.  Asterisks indicate significant differences between experimental groups 
(Kruskal-Wallis test with Dunn’s Multiple Comparison test; *** p<0.0001).  Bars 
represent the standard error of the mean (s.e.m.).  N= A total of 460 to 513 SGCs 
analyzed per treatment group. 
***	   ***	  
***	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4.3.4 Satellite glial cell connexin 43 expression 
 
 Preliminary results on two sections from two animals from each experimental 
group showed a qualitative increase in connexin 43, a component of cellular gap 
junctions, in the SGC region in the p75NTR AS infused treatment group compared to the 
non-infused control group (Figure 4.3.4).  This increase in connexin 43 immunoreactivity 
was most evident around large size neurons. 
 
4.3.5 Satellite glial cell number increase 
 
Preliminary results showed a quantitative increase in the number of SGCs in the 
p75NTR AS infused treatment group compared to the non-infused control group (Figure 
4.3.5).  Preliminary quantitative analysis was performed to determine the average number 
of SGCs surrounding individual neurons was performed whereby all SGC nuclei 
surrounding every individual neuron in two sections from two animals from each 
experimental group were counted then divide by the total number of neurons analysed.  
This revealed that in the non-infused control group, an average of four to five SGCs 
surrounding individual neurons was observed.  With the infusion of p75NTR AS, an 
approximate doubling in the number of SGCs surrounding each neuron was observed.  
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Figure 4.3.4 Satellite glial cell connexin 43 immunoreactive labeling intensity is 
increased with p75NTR AS treatment. Fluorescence photomicrographs of L5 DRG 
sections processed for immunohistochemistry depict connexin 43 protein expression in 
the cytoplasm of SGCs from uninjured intact rats in control non-infused (A) and p75NTR 
AS infused (B).  Note: Intrathecal infusion of p75NTR AS OGN (B) results in increased 
expression of connexin 43 in SGCs compared to the control non-infused (A) treatment 
group.  Scale bar = 50 µm 
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Figure 4.3.5 Satellite glial cell number is increased with p75NTR AS treatment.   
Fluorescence photomicrographs of L5 DRG sections labeled with DAPI depict the 
number of SGCs from uninjured intact rats in control non-infused (A) and p75NTR AS 
infused (B).  Note: Intrathecal infusion of p75NTR AS OGN (B) results in increased 
number of SGCs compared to the control non-infused (A) treatment group.  Scale bar = 
50 µm 
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5. Discussion 
5.1 Summary of major findings  
Work performed for this thesis revealed that: 1) the intrathecal infusion of 
p75NTR AS resulted in significantly decreased neuronal p75NTR protein levels; 2) the 
p75NTR AS uptake in the DRG appeared restricted to only the sensory neurons, not the 
SGCs; 3) reduced neuronal p75NTR did not result in significantly altered NaV1.8, NaV1.9 
or TrkA expression in the DRG; 4) reduced neuronal p75NTR was associated with 
induction of a ‘reactive state’ in SGCs consisting of significantly increased expression of 
GFAP and p75NTR and significantly decreased Kir4.1 expression.  In addition, 
preliminary experiments revealed that the altered phenotype induced by p75NTR AS also 
corresponded with an increase in the number of SGCs surrounding each neuron and an 
elevated expression of the gap junction protein connexin 43, suggesting that cell-cell 
connectivity/communication was also altered.   
These experiments utilized an intrathecal AS infusion technique previously 
employed by our laboratory (Wilson-Gerwing et al., 2009).  By infusing a small quantity 
of p75NTR AS over 7 days in the intrathecal space of the spinal cord, its uptake is only 
visualized in DRG neurons, presumably due to uptake by the axons proximal to the 
infusion site.  The SGCs in the corresponding DRG, appear not to have taken up the 
p75NTR AS as there was no accumulation of the fluorescent signal in these cells and no 
reduction in p75NTR protein expression. The confinement of the p75NTR AS to only the 
neurons was consistent with the distribution that we also observed when we intrathecally 
administered siRNA (Geremia et al., 2010).  Further, this low dose of p75NTR AS over a 
7 day period, although sufficient to significantly decrease neuronal cytoplasmic p75NTR 
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levels in non-injured DRG, appeared to do so without inducing nonspecific/inflammatory 
effects, as evidenced by a lack of increase in the cell stress marker, ATF-3, and the 
immunological cell marker, ED-1 (JN, data not shown).  Finally, this intrathecal infusion 
technique has been used by several labs (Barclay et al., 2002; Lai et al., 2002; Obata et 
al., 2006; Wilson-Gerwing et al., 2009) to deliver a variety of AS to DRG neurons.  
Consistent with our findings, previous studies employing the same p75NTR AS 
sequences have noted marked reductions in neuronal p75NTR protein expression as 
detected immunohistochemically (Obata et al., 2006; Wilson-Gerwing et al., 2009).   
Preliminary behavioural testing was performed on these animals to determine 
whether infusion of p75NTR AS in the absence of a nerve injury was sufficient to alter 
the latency of paw lifts in a thermal hyperalgesia test.  Consistent with a previous report 
(Obata et al., 2006), no changes were observed in basal pain sensitivity (JN, personal 
observations).  
 
5.2 Reduced expression of p75NTR in sensory neurons does not significantly impact    
Na+ channel nor TrkA expression   
Nociception, the ability to sense noxious stimuli, is fundamental to the survival of 
an organism.  When excessive chemical, mechanical or thermal stimuli is applied to 
tissue, nociceptive nerve fibers depolarize, which initiates action potentials. Maintaining 
a baseline threshold for action potentials is essential to the accurate transmission of 
sensory information; if the threshold is decreased, aberrant neural firing may occur, 
creating a neuropathic pain state.  This baseline threshold is contingent on the proper 
functioning of voltage and proton-gated Ca2+, K+ and Na+ ionic channels.  Associated 
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with the transmission of pain and blocked by the commonly known analgesic Lidocaine® 
are voltage-gated Na+ channels 1.8 (NaV1.8) and 1.9 (NaV1.9) (reviewed in Blair and 
Bean, 2002; Priest and Kaczorowski, 2007).  These channels are responsible for the 
majority of the inward action potential current and significant increases in their 
expression levels, such as that which occurs with injury, alters the neuronal excitability 
threshold.  This hypersensitive state allows for aberrant action potential firing, 
experienced as chronic neuropathic pain (Blair and Bean, 2002; Lai et al., 2004; Waxman 
et al., 1999).  NaV1.8 and NaV1.9 are highly expressed within the TrkA-expressing 
nociceptive neuronal subpopulation; over 80% are positive for NaV1.8, and NaV1.9 
expression is reported to be limited to only this subpopulation within the DRG (Djouhri 
et al., 2003a; Fang et al., 2002), as well as in all of the IB4 positive, GDNF-responsive 
subpopulation (Fukuoka et al., 2008). 
We report here that no significant changes in the expression levels of NaV1.8, 
NaV1.9 or TrkA were observed in the DRG and sciatic nerves when neuronal expression 
levels of p75NTR protein were significantly decreased for 7 days in intact/non-injured 
animals by AS treatment.  It is of note though that there was a slight shift in the size 
range of neurons that immunolabel for NaV1.8.  It is expressed in all size ranges of 
neurons in naïve or p75NTR SC treated animals but p75NTR AS treatment results in very 
few large (>50 mm) being highly immunoreactive for NaV1.8.  A similar shift has been 
observed regarding the TrkA subpopulation following an axotomy (Li et al., 2000).  This 
change in TrkA immunoreactivity distribution was however attributed to a progressive 
shrinking in neuron size over time.  Although little variation was observed after one 
week, differences were most remarkable at two weeks post-injury.  We however failed to 
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identify many large TrkA-immunopositive neurons regardless of treatment condition.  It 
is thus unknown as to whether this shift in NaV1.8 immunoreactivity was in the 
subpopulation colocalized with TrkA or without.  Investigations with a more prolonged 
infusion timeline and in situ hybridization may elucidate more on this observed size shift 
in Na+ channel expression. 
Regulation of these Na+ channels has been postulated to be via different 
neurotrophic signaling pathways: neurotophins via the Trk receptors, neurotrophins via 
the p75NTR or GDNF via its own receptor.  It is known that maintaining endogenous 
levels of NGF and GDNF are necessary for preserving NaV1.8 and NaV1.9 neuronal 
expression levels (Black et al., 1997; Cummins et al., 2000; Dib-Hajj et al., 1998; Fjell et 
al., 1999).  It has been assumed that NGF’s actions are via TrkA for regulating Na+ 
channel levels, however p75NTR was not considered as an alternative signaling pathway 
(Fang et al., 2005).  Given the results of this study, it suggests that the dominant signaling 
pathways, in the absence of an injury or inflammation, for homeostatic maintenance of 
NaV1.8 and NaV1.9 are the NGF/TrkA pathway in the TrkA/p75NTR positive 
subpopulation and the GDNF/GDNF-α receptor pathway in the IB4 positive/p75NTR 
negative subpopulation.  Thus, decreasing endogenous neuronal p75NTR in the absence 
of an injury appears not to significantly affect neuronal Na+ channel levels although it 
may be that a critical p75NTR reduction threshold had not yet been met.  
When introduced in conjunction with a compression nerve injury, p75NTR AS or 
inhibitory antibody has been shown to diminish hyperalgesia in response to both thermal 
and mechanical noxious stimuli (Fukui et al., 2010; Obata et al., 2006), supporting the 
involvement of p75NTR in neuropathic pain states.  More research into the interaction 
	   80	  
between the various neurotrophins, the Trk receptors and p75NTR with and without an 
injury is needed to further refine this hypothesis. 
  
5.3 Reduced neuronal p75NTR expression induces a dramatic switch in satellite glial 
cell phenotype to one of a reactive state  
Numerous studies have implicated glial cells of the central nervous system in the 
promotion and/or preservation of neuropathic pain states (Clark et al., 2007; Coull et al., 
2005; Guo et al., 2007).  In contrast, very little is known about the glial cells of the 
peripheral nervous system and their involvement in the neuropathic pain syndrome.  
Recent findings have implicated a glial cell type unique to the peripheral nervous system, 
the SGC’s, in neuropathic pain states resulting from peripheral nerve injuries.  SGCs 
tightly encapsulate the cell bodies of sensory neurons within the DRG and are thus 
optimally positioned to help maintain a homeostatic environment, influencing neuronal 
excitability.  The SGCs buffer the perineuronal area and correspondingly express K+ 
channels Kir4.1 and SK3 (Hibino et al., 1999; Vit et al., 2006), Ca2+-binding S100 proteins 
(Sandelin et al., 2004; Vega et al., 1991), glutamate transporters (Berger and Hediger, 
2000; Hosli and Hosli, 1978), glutamine synthetase (Miller et al., 2002; Weick et al., 
2003) and gap junction proteins permitting the passage of K+ and other small molecules 
between adjacent SGCs (Huang et al., 2005; Konishi, 1996; Weick et al., 2003).  With a 
peripheral nerve injury or inflammation, changes have been observed in some of these 
molecules as well as others.  The SGCs become ‘reactive’ and express higher levels of 
GFAP, p75NTR, the gap junction constituent, connexin 43, and lower levels of Kir4.1 
(Ohara et al., 2008; Tang et al., 2010; Zhou et al., 1996).  The SGCs also undergo marked 
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morphological changes with injury; they become hypertrophic, they proliferate and they 
increase their coupling with one another via gap junctions (reviewed in Pannese, 1981).  
Our findings demonstrate a very robust induction of a ‘reactive-like’ state in the 
SGCs, in the absence of an injury or inflammation, in response to a significant reduction 
in neuronal p75NTR protein.  This ‘reactive-like’ state is reminiscent of an injury  
phenotype; the SGCs expressed significantly higher protein levels of GFAP, p75NTR and 
significantly lower levels of Kir4.1 protein.  Preliminary qualitative observations also 
show an increase in the number of SGCs around each neuron and an increase in connexin 
43 protein following neuronal p75NTR AS treatment.  This glial reactivity was also 
induced in the Schwann cells of the sciatic nerve with an observed increase in GFAP.  
Therefore, the data presented in this thesis demonstrate that neuronal signaling via 
neuronal p75NTR appears to be necessary to maintain a homeostatic, ‘non-activated’ 
state in the SGCs.  It is thus demonstrated that the reduction of neuronal p75NTR 
modulates the sensory neuron/SGC communication axis.  The signaling complex 
responsible for this phenomenon is currently unknown.  
Nerve injuries or inflammation also promote the infiltration of immune cells into 
the perineuronal area that morphologically resemble SGCs (Hu and McLachlan, 2003; 
van Velzen et al., 2009).  Thus, it is possible that some of the observed perineuronal cells 
may also be resident immune cells (Lu and Richardson, 1993) as the SGC population has 
not been rigorously defined, however the markers (GFAP, Kir4.1, connexin 43, etc) 
localized to this area are consistent with the majority being glial cells.  In addition, no 
apparent increase in the ED1 (marker for activated macrophages) was observed following 
p75NTR AS infusion (data not shown) suggesting that an inflammatory response was not 
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induced.  Despite this, it cannot be ruled out that a minor portion of the proliferating cells 
may be resident immune cells, although this was not determined in my studies.  
 
5.3.1 Sensory neuron/glial communication 
 Very little is currently known regarding sensory neuron/SGC communication.  It 
is assumed that these cells communicate, given the symbiotic relationship they appear to 
maintain, however limited evidence of this liaison has emerged to date.  The first 
observation of this phenomenon was described via chemical signaling involving nitric 
oxide, released by the neurons in response to N-methyl-D-aspartate receptor activation, 
which initiated the release of cyclic guanosine 3′,5′-monophosphate from the SGCs 
(Magnusson et al., 2000; Meller et al., 1992; Thippeswamy and Morris, 1997). A parallel 
upregulation of nitric oxide synthase (NOS) in neurons and cyclic guanosine 3′,5′-
monophosphate in the SGCs directly after axotomy supports Thippeswamy and Morris’ 
(1997) hypothesis of nitric oxide acting as a neuron-glial signaling molecule, possibly 
promoting neural survival (Shi et al., 1998).  However, it is unlikely that nitric oxide is 
responsible for the SGC ‘reactivity’ resulting from reduced neuronal p75NTR in these 
sets of experiments as only approximately 10% of sensory neurons express NOS in a 
non-injured state (Shi et al., 1998).  However, this rapidly increases to 35% two days then 
45% one week after peripheral nerve injury (Verge et al., 1992).  Whether increased 
neuronal expression of NOS resulted from the p75NTR AS treatment was not examined. 
Since then, in addition to further research on the nitric oxide communication axis, 
SGCs have been shown to respond to neuronal releases of adenosine triphosphate (ATP) 
in several different ways.  The first is the activation of P2X ionotropic and/or P2Y 
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metabotropic ATP purinoreceptors (Kobayashi et al., 2005, 2006).  Their activation can 
commence calcium-mediated depolarizations amongst SGCs, propagated via their gap 
junctions (Suadicani et al., 2010).  The second is the neuronal release of ATP, stimulating 
SGCs to also release their own ATP and tumour necrosis factor α , both exerting an 
excitatory effect on the sensory neurons (Zhang et al., 2007).  Injured tissue releases ATP 
that can initiate an ‘activation’ of purinoreceptors (reviewed in Burnstock and Wood, 
1996), whereas with the p75NTR AS infusion, this factor is missing.  The mode of 
neuron/glial communication responsible for the observed changes in SGC properties in 
this thesis remains to be elucidated. 
 
5.3.2 Satellite glial cell activation 
The intrathecal infusion of p75NTR AS resulted in a very robust induction of a 
‘reactive-like’ state, evidenced by GFAP immunoreactivity, in the SGCs of the DRG.  
This reactivity was greatest in the SGCs surrounding neurons that did not label for IB4, 
which by definition, expressed p75NTR (McMahon et al., 1994; Wright and Snider, 
1995).  In the DRG, I noted that SGCs express very low levels of GFAP under normal 
conditions in agreement with Vit et al. (2006).  Following an injury or chronic 
inflammation, GFAP levels steadily increase until most SGCs are GFAP-immunoreactive 
(Siemionow et al., 2009).  This increase in GFAP correlated with an increase in SGC 
p75NTR immunoreactivity.  Perineuronal cell p75NTR expression is also upregulated 
following a nerve injury (Zhou et al., 1996), but is normally expressed at low levels under 
nonpathological conditions (Obata et al., 2006). 
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In addition to changes in GFAP and p75NTR in the perineuronal area, an increase 
in TrkA protein expression was observed in what appeared to be fine axonal processes.  
SGCs have not been reported to express TrkA mRNA, however sympathetic nerve axons 
have detectable trkA protein (Martin-Zanca et al., 1990; Tessarollo et al., 1993). 
These TrkA positive structures resembled rings around some of the neuronal cell 
bodies.  Sympathetic nerve axons will sprout around the cell bodies of nociceptive 
neurons positive for TrkA, in 98% of cases, forming basket-like structures in response to 
nerve injuries (McLachlan et al., 1993; Walsh et al., 1999).  It has been observed that 
these basket-like formations are closely associated with increased SGC p75NTR levels 
and SGC neurotrophin expression (Zhou et al., 1999; Zhou et al., 1996).  It has been 
shown that sprouting sympathetic axons follow myelinated sensory axons and wrap 
around the SGCs, but are not directly juxtaposed to the neuronal cell body (Ramer and 
Bisby, 1998, 1999) perhaps as a result of tropic gradients set up by the increased 
expression of neurotrophins in the reactive SGCs.  Of note, their sprouting is reduced in 
p75NTR knockout mice (Ramer and Bisby, 1997) perhaps because the perineuronal cells 
do not induce the same reactive state.  Thus, it appears that the reduction of neuronal 
p75NTR may have indirectly induced sympathetic nerve axon sprouting by upregulating 
expression of neurotrophins in conjunction with the other markers of the reactive state, 
although this was not ascertained. 
 With such a significant increase in the cytoskeletal protein, GFAP, akin to an 
injury state, we postulated that the SGCs may be proliferating and increasing their 
coupling, as it has been shown that SGCs undergo changes in cell coupling and gap 
junction protein expression levels following a nerve injury (Gunjigake et al., 2009).  
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Although we did not look at coupling directly, preliminary results revealed an increase in 
the mean number of SGCs around each neuronal cell body and an increase in the gap 
junction protein, connexin 43, which has previously been localized to astrocytes and 
SGCs (Nagy et al., 1997; Ohara et al., 2008).  It has been postulated by some that the 
ratio of SGCs per neuronal cell body is regulated by the metabolic requirements of that 
neuron (Pannese, 1981; Zimmermann and Braun, 1999).  Thus, the infusion of p75NTR 
AS may be altering the metabolic function of the sensory neurons that in turn, requires 
the activation and proliferation of SGCs to cope with these changes. 
 
5.3.3 Satellite glial cells as therapeutic targets for pain control   
The most insightful experiments undertaken to investigate the role of SGCs in the 
regulation of pain pathways have employed the use of AS, RNA interference (RNAi) or 
silencing RNA (siRNA) technology.  These techniques involve reducing or near complete 
silencing of a molecule of interest in non-injured/intact animal models.  These 
investigations have provided solid data supporting roles for Kir4.1 and connexin 43 in 
SGCs in regulating neuropathic pain states and may help in identifying novel therapeutic 
targets for pain control. 
The silencing of connexin 43 in the SGCs by RNAi has been investigated by 
Ohara et al. (2008), Procacci et al. (2008) and Vit et al. (2006).  It appears that the 
behavioural response following the injection of connexin 43 double stranded RNA 
depends on whether a nerve injury is present or not: pain-like behaviour was reduced 
after a nerve compression and pain-like behaviour was induced in the absence of an 
injury (Ohara et al., 2008).  Thus, it appears that connexin 43 expression levels, if not 
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kept within an optimal range, can significantly contribute to the development of a 
neuropathic pain state.  We report that the significant reduction of neuronal p75NTR 
induced an upregulation of connexin 43 in SGCs within the DRG, albeit no behavioural 
consequences were observed upon preliminary examination of nociceptive thresholds 
(JN, personal observations).  It is possible that more effective silencing of neuronal 
p75NTR protein production with the use of RNAi or siRNA might produce a more robust 
upregulation of connexin 43 to the point of inducing pain-like behaviour (Ohara et al., 
2008) or alternatively additional factors not expressed in the current experiments are 
required for this response.  Another molecule of interest, Kir4.1 has been associated with 
neuropathic pain.  Vit et al. (2008) reported that an injection of double stranded RNA 
(RNAi technology) targeting Kir4.1 into the trigeminal nerve, in the absence of a nerve 
injury, was sufficient to induce pain-like behaviour in rats.  The outcome of introducing 
Kir4.1 RNAi post-injury is currently unknown.  We report that the significant reduction of 
neuronal p75NTR induced a downregulation of Kir4.1 in SGCs within the DRG, albeit no 
behavioural changes were observed.  It is possible that more effective silencing of 
neuronal p75NTR with the use of RNAi or siRNA, in the same case as connexin 43, may 
significantly downregulate Kir4.1 expression and induce pain-like behaviour. Unlike all 
other markers examined, Kir4.1 was the only marker where a significant change was 
observed in response to p75NTR SC infusion.  Kir4.1 has been described as highly 
sensitive to extracellular K+ concentration fluctuations (reviewed in Olsen and 
Sontheimer, 2008).  Its expression pattern, spatially and temporally, in SGCs, positively 
correlates with neuron size (Durham and Garrett, 2010).  Proper uptake of glutamate in 
astrocytes is most effective at a negative resting potential, a parameter directly contingent 
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on Kir4.1 functioning (Kucheryavykh et al., 2007), suggesting a similar role in SGCs.  
Thus, this may reflect Kir4.1 and SGCs’ ultra sensitivity to any perturbation of the 
homeostatic state within the sensory system. 
In conclusion, the findings in my thesis support a critical role for neuronal 
p75NTR signaling in the maintenance of the homeostatic state in sensory neurons with 
respect to SGCs transition to a reactive state associated with a number of pathologies.  
SGCs are now being recognized as key modulators of neuropathic pain states and are thus 
potential therapeutic targets (Capuano et al., 2009).  Elucidating the messengers 
responsible for the communication axis between the SGCs and their sensory neurons and 
the factors that transition these cells from normal to pathological states will aid in 
understanding the mechanism of neuropathic pain and the generation of novel 
therapeutics. 
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